drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
sequencelengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
sequencelengths 1
10
| all_paths_str
sequencelengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB06822 | DB10897 | 802 | 539 | [
"DDInter1812",
"DDInter291"
] | Tinzaparin | Capsicum | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. | Capsicum (Chili pepper) allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
802,
23,
539
]
],
[
[
802,
64,
885
],
[
885,
23,
539
]
],
[
[
802,
25,
578
],
[
578,
23,
539
]
],
[
[
802,
25,
1421
],
[
1421,
62,
539
]
],
[
[
802,
64,
885
],
[
885,
63,
702
],
[
702,
23,
539
]
],
[
[
802,
64,
702
],
[
702,
24,
885
],
[
885,
23,
539
]
],
[
[
802,
64,
553
],
[
553,
25,
885
],
[
885,
23,
539
]
],
[
[
802,
64,
1061
],
[
1061,
1,
885
],
[
885,
23,
539
]
],
[
[
802,
25,
578
],
[
578,
63,
885
],
[
885,
23,
539
]
],
[
[
802,
64,
1213
],
[
1213,
64,
885
],
[
885,
23,
539
]
]
] | [
[
[
"Tinzaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound)",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
]
] | Tinzaparin may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tinzaparin may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tinzaparin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tinzaparin may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tinzaparin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tinzaparin may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tinzaparin may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tinzaparin may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tinzaparin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum |
DB00808 | DB11348 | 1,605 | 1,065 | [
"DDInter916",
"DDInter279"
] | Indapamide | Calcium Phosphate | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets. Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency. When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. Interestingly, | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1605,
24,
1065
]
],
[
[
1605,
62,
1620
],
[
1620,
24,
1065
]
],
[
[
1605,
40,
811
],
[
811,
24,
1065
]
],
[
[
1605,
23,
1669
],
[
1669,
24,
1065
]
],
[
[
1605,
62,
1620
],
[
1620,
62,
1014
],
[
1014,
24,
1065
]
],
[
[
1605,
62,
964
],
[
964,
23,
1014
],
[
1014,
24,
1065
]
],
[
[
1605,
40,
811
],
[
811,
40,
1014
],
[
1014,
24,
1065
]
],
[
[
1605,
23,
1669
],
[
1669,
62,
1014
],
[
1014,
24,
1065
]
],
[
[
1605,
24,
842
],
[
842,
24,
943
],
[
943,
63,
1065
]
],
[
[
1605,
62,
1545
],
[
1545,
40,
1620
],
[
1620,
24,
1065
]
]
] | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Indapamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Indapamide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Indapamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Indapamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Indapamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Indapamide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Indapamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
],
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Indapamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
]
] | Indapamide may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Indapamide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Indapamide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Indapamide may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Indapamide may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Indapamide (Compound) resembles Metolazone (Compound) and Metolazone (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Indapamide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate and Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Indapamide may cause a minor interaction that can limit clinical effects when taken with Oxytetracycline and Oxytetracycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate |
DB00478 | DB01362 | 1,369 | 497 | [
"DDInter1597",
"DDInter960"
] | Rimantadine | Iohexol | An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1369,
25,
497
]
],
[
[
1369,
21,
28787
],
[
28787,
60,
497
]
],
[
[
1369,
40,
1170
],
[
1170,
25,
497
]
],
[
[
1369,
63,
1503
],
[
1503,
25,
497
]
],
[
[
1369,
25,
593
],
[
593,
25,
497
]
],
[
[
1369,
21,
28787
],
[
28787,
60,
258
],
[
258,
40,
497
]
],
[
[
1369,
21,
28662
],
[
28662,
60,
1523
],
[
1523,
24,
497
]
],
[
[
1369,
40,
1170
],
[
1170,
21,
28681
],
[
28681,
60,
497
]
],
[
[
1369,
63,
1503
],
[
1503,
21,
28787
],
[
28787,
60,
497
]
],
[
[
1369,
54,
19350
],
[
19350,
15,
1170
],
[
1170,
25,
497
]
]
] | [
[
[
"Rimantadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Rimantadine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iohexol"
]
],
[
[
"Rimantadine",
"{u} (Compound) resembles {v} (Compound)",
"Amantadine"
],
[
"Amantadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Rimantadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
],
[
"Lindane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Rimantadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Rimantadine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iodixanol"
],
[
"Iodixanol",
"{u} (Compound) resembles {v} (Compound)",
"Iohexol"
]
],
[
[
"Rimantadine",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused by {v} (Compound)",
"Labetalol"
],
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Rimantadine",
"{u} (Compound) resembles {v} (Compound)",
"Amantadine"
],
[
"Amantadine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iohexol"
]
],
[
[
"Rimantadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
],
[
"Lindane",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iohexol"
]
],
[
[
"Rimantadine",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"M2 Protein Inhibitors"
],
[
"M2 Protein Inhibitors",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Amantadine"
],
[
"Amantadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
]
] | Rimantadine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iohexol (Compound)
Rimantadine (Compound) resembles Amantadine (Compound) and Amantadine may lead to a major life threatening interaction when taken with Iohexol
Rimantadine may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may lead to a major life threatening interaction when taken with Iohexol
Rimantadine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Iohexol
Rimantadine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iodixanol (Compound) and Iodixanol (Compound) resembles Iohexol (Compound)
Rimantadine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Labetalol (Compound) and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Rimantadine (Compound) resembles Amantadine (Compound) and Amantadine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Rimantadine may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iohexol (Compound)
Rimantadine (Compound) is included by M2 Protein Inhibitors (Pharmacologic Class) and M2 Protein Inhibitors (Pharmacologic Class) includes Amantadine (Compound) and Amantadine may lead to a major life threatening interaction when taken with Iohexol |
DB00331 | DB15093 | 1,645 | 1,654 | [
"DDInter1164",
"DDInter1698"
] | Metformin | Somapacitan | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes. Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995. | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020. | Moderate | 1 | [
[
[
1645,
24,
1654
]
],
[
[
1645,
63,
168
],
[
168,
23,
1654
]
],
[
[
1645,
63,
176
],
[
176,
24,
1654
]
],
[
[
1645,
24,
351
],
[
351,
24,
1654
]
],
[
[
1645,
62,
1647
],
[
1647,
24,
1654
]
],
[
[
1645,
63,
168
],
[
168,
24,
10
],
[
10,
24,
1654
]
],
[
[
1645,
63,
176
],
[
176,
24,
168
],
[
168,
23,
1654
]
],
[
[
1645,
24,
351
],
[
351,
63,
10
],
[
10,
24,
1654
]
],
[
[
1645,
24,
1512
],
[
1512,
24,
473
],
[
473,
24,
1654
]
],
[
[
1645,
24,
473
],
[
473,
63,
168
],
[
168,
23,
1654
]
]
] | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Metformin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
]
] | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Metformin may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan |
DB00176 | DB00471 | 529 | 201 | [
"DDInter770",
"DDInter1242"
] | Fluvoxamine | Montelukast | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticosteroids or other agents in asthma step therapy. Regardless, in 2008-2009, there were FDA-led investigations into the possibility of montelukast to elicit neuropsychiatric effects like agitation, hallucinations, suicidal behaviour, and others in individuals who used the medication. And although these kinds of effects are currently included in the official prescribing information for montelukast,[L6301,L6304,L6307,L6310,L6325,L6328,L6331] the drug still sees extensive use worldwide via millions of prescriptions annually and has since become available as a generic and as a brand name product. | Moderate | 1 | [
[
[
529,
24,
201
]
],
[
[
529,
6,
6017
],
[
6017,
45,
201
]
],
[
[
529,
21,
28787
],
[
28787,
60,
201
]
],
[
[
529,
24,
1017
],
[
1017,
63,
201
]
],
[
[
529,
24,
254
],
[
254,
24,
201
]
],
[
[
529,
6,
6017
],
[
6017,
45,
1548
],
[
1548,
24,
201
]
],
[
[
529,
21,
28787
],
[
28787,
60,
1051
],
[
1051,
24,
201
]
],
[
[
529,
21,
29231
],
[
29231,
60,
1377
],
[
1377,
63,
201
]
],
[
[
529,
24,
1017
],
[
1017,
64,
913
],
[
913,
63,
201
]
],
[
[
529,
24,
1220
],
[
1220,
5,
11649
],
[
11649,
44,
201
]
]
] | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Montelukast"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Montelukast"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Trimethoprim"
],
[
"Trimethoprim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) treats {v} (Disease)",
"asthma"
],
[
"asthma",
"{u} (Disease) is treated by {v} (Compound)",
"Montelukast"
]
]
] | Fluvoxamine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Montelukast (Compound)
Fluvoxamine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Montelukast (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Montelukast
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Montelukast
Fluvoxamine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trimethoprim (Compound) and Trimethoprim may cause a moderate interaction that could exacerbate diseases when taken with Montelukast
Fluvoxamine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Aminoglutethimide (Compound) and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Montelukast
Fluvoxamine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Montelukast
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Montelukast
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) treats asthma (Disease) and asthma (Disease) is treated by Montelukast (Compound) |
DB09074 | DB11652 | 1,362 | 1,155 | [
"DDInter1327",
"DDInter1891"
] | Olaparib | Tucatinib | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens. | Major | 2 | [
[
[
1362,
25,
1155
]
],
[
[
1362,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
1362,
64,
609
],
[
609,
24,
1155
]
],
[
[
1362,
63,
522
],
[
522,
24,
1155
]
],
[
[
1362,
24,
1320
],
[
1320,
63,
1155
]
],
[
[
1362,
24,
98
],
[
98,
24,
1155
]
],
[
[
1362,
25,
351
],
[
351,
64,
1155
]
],
[
[
1362,
64,
1510
],
[
1510,
25,
1155
]
],
[
[
1362,
63,
134
],
[
134,
25,
1155
]
],
[
[
1362,
24,
283
],
[
283,
64,
1155
]
]
] | [
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tucatinib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
]
] | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Olaparib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Olaparib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Tucatinib
Olaparib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Tucatinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may lead to a major life threatening interaction when taken with Tucatinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Tucatinib |
DB00204 | DB09098 | 228 | 98 | [
"DDInter580",
"DDInter1700"
] | Dofetilide | Somatrem | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
228,
24,
98
]
],
[
[
228,
25,
608
],
[
608,
23,
98
]
],
[
[
228,
24,
159
],
[
159,
63,
98
]
],
[
[
228,
25,
11
],
[
11,
24,
98
]
],
[
[
228,
24,
455
],
[
455,
24,
98
]
],
[
[
228,
25,
124
],
[
124,
63,
98
]
],
[
[
228,
40,
540
],
[
540,
24,
98
]
],
[
[
228,
23,
891
],
[
891,
24,
98
]
],
[
[
228,
23,
1101
],
[
1101,
25,
98
]
],
[
[
228,
25,
608
],
[
608,
24,
159
],
[
159,
63,
98
]
]
] | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dofetilide",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somatrem"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
]
] | Dofetilide may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Dofetilide may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Dofetilide may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Dofetilide (Compound) resembles Dronedarone (Compound) and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somatrem
Dofetilide may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem |
DB00686 | DB09030 | 383 | 840 | [
"DDInter1424",
"DDInter1945"
] | Pentosan polysulfate | Vorapaxar | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation. | Moderate | 1 | [
[
[
383,
24,
840
]
],
[
[
383,
24,
765
],
[
765,
24,
840
]
],
[
[
383,
24,
1496
],
[
1496,
63,
840
]
],
[
[
383,
63,
1061
],
[
1061,
24,
840
]
],
[
[
383,
63,
702
],
[
702,
25,
840
]
],
[
[
383,
24,
500
],
[
500,
25,
840
]
],
[
[
383,
24,
283
],
[
283,
64,
840
]
],
[
[
383,
24,
765
],
[
765,
63,
885
],
[
885,
24,
840
]
],
[
[
383,
24,
885
],
[
885,
23,
944
],
[
944,
62,
840
]
],
[
[
383,
63,
1061
],
[
1061,
23,
944
],
[
944,
62,
840
]
]
] | [
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vorapaxar"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vorapaxar"
]
]
] | Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Vorapaxar
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Vorapaxar
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Vorapaxar
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar |
DB04868 | DB13074 | 478 | 877 | [
"DDInter1293",
"DDInter1110"
] | Nilotinib | Macimorelin | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. | Major | 2 | [
[
[
478,
25,
877
]
],
[
[
478,
62,
112
],
[
112,
23,
877
]
],
[
[
478,
24,
1320
],
[
1320,
24,
877
]
],
[
[
478,
64,
651
],
[
651,
24,
877
]
],
[
[
478,
63,
673
],
[
673,
24,
877
]
],
[
[
478,
25,
913
],
[
913,
24,
877
]
],
[
[
478,
62,
479
],
[
479,
24,
877
]
],
[
[
478,
24,
1654
],
[
1654,
63,
877
]
],
[
[
478,
64,
485
],
[
485,
25,
877
]
],
[
[
478,
24,
144
],
[
144,
25,
877
]
]
] | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
]
] | Nilotinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Nilotinib may lead to a major life threatening interaction when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Nilotinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Nilotinib may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may lead to a major life threatening interaction when taken with Macimorelin |
DB00860 | DB00991 | 891 | 97 | [
"DDInter1513",
"DDInter1358"
] | Prednisolone | Oxaprozin | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Moderate | 1 | [
[
[
891,
24,
97
]
],
[
[
891,
63,
362
],
[
362,
1,
97
]
],
[
[
891,
63,
1274
],
[
1274,
24,
97
]
],
[
[
891,
62,
307
],
[
307,
1,
97
]
],
[
[
891,
63,
1236
],
[
1236,
40,
97
]
],
[
[
891,
5,
11577
],
[
11577,
49,
97
]
],
[
[
891,
21,
29017
],
[
29017,
60,
97
]
],
[
[
891,
1,
1486
],
[
1486,
24,
97
]
],
[
[
891,
40,
251
],
[
251,
24,
97
]
],
[
[
891,
62,
1018
],
[
1018,
24,
97
]
]
] | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Prednisolone",
"{u} (Compound) treats {v} (Disease)",
"rheumatoid arthritis"
],
[
"rheumatoid arthritis",
"{u} (Disease) is palliated by {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Prednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating increased"
],
[
"Sweating increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
]
] | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Oxaprozin (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Oxaprozin (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Oxaprozin (Compound)
Prednisolone (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is palliated by Oxaprozin (Compound)
Prednisolone (Compound) causes Sweating increased (Side Effect) and Sweating increased (Side Effect) is caused by Oxaprozin (Compound)
Prednisolone (Compound) resembles Methylprednisolone (Compound) and Methyl
Prednisolone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin |
DB00496 | DB00981 | 194 | 1,528 | [
"DDInter480",
"DDInter1463"
] | Darifenacin | Physostigmine (ophthalmic) | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments. | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | Moderate | 1 | [
[
[
194,
24,
1528
]
],
[
[
194,
21,
28658
],
[
28658,
60,
1528
]
],
[
[
194,
24,
1511
],
[
1511,
63,
1528
]
],
[
[
194,
24,
543
],
[
543,
24,
1528
]
],
[
[
194,
35,
262
],
[
262,
24,
1528
]
],
[
[
194,
63,
701
],
[
701,
24,
1528
]
],
[
[
194,
74,
352
],
[
352,
24,
1528
]
],
[
[
194,
24,
593
],
[
593,
64,
1528
]
],
[
[
194,
21,
28658
],
[
28658,
60,
1592
],
[
1592,
63,
1528
]
],
[
[
194,
24,
1511
],
[
1511,
21,
28658
],
[
28658,
60,
1528
]
]
] | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Darifenacin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Physostigmine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Darifenacin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Darifenacin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Physostigmine"
]
],
[
[
"Darifenacin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nebivolol"
],
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Physostigmine"
]
]
] | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Darifenacin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Physostigmine (Compound)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Darifenacin (Compound) resembles Clidinium (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Darifenacin (Compound) resembles Trospium (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Physostigmine
Darifenacin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Nebivolol (Compound) and Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Physostigmine (Compound) |
DB01142 | DB01362 | 1,264 | 497 | [
"DDInter593",
"DDInter960"
] | Doxepin | Iohexol | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1264,
25,
497
]
],
[
[
1264,
21,
28681
],
[
28681,
60,
497
]
],
[
[
1264,
63,
323
],
[
323,
24,
497
]
],
[
[
1264,
24,
819
],
[
819,
24,
497
]
],
[
[
1264,
64,
494
],
[
494,
24,
497
]
],
[
[
1264,
24,
1592
],
[
1592,
63,
497
]
],
[
[
1264,
62,
471
],
[
471,
24,
497
]
],
[
[
1264,
63,
999
],
[
999,
25,
497
]
],
[
[
1264,
25,
318
],
[
318,
25,
497
]
],
[
[
1264,
24,
1267
],
[
1267,
64,
497
]
]
] | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Doxepin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iohexol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetazolamide"
],
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
],
[
"Amifampridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
]
] | Doxepin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Doxepin may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Doxepin may cause a minor interaction that can limit clinical effects when taken with Acetazolamide and Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when taken with Iohexol
Doxepin may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may lead to a major life threatening interaction when taken with Iohexol
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine and Amifampridine may lead to a major life threatening interaction when taken with Iohexol |
DB00938 | DB09083 | 455 | 880 | [
"DDInter1635",
"DDInter996"
] | Salmeterol | Ivabradine | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects. | Moderate | 1 | [
[
[
455,
24,
880
]
],
[
[
455,
24,
480
],
[
480,
24,
880
]
],
[
[
455,
24,
159
],
[
159,
63,
880
]
],
[
[
455,
23,
1220
],
[
1220,
24,
880
]
],
[
[
455,
63,
1559
],
[
1559,
24,
880
]
],
[
[
455,
24,
39
],
[
39,
25,
880
]
],
[
[
455,
25,
351
],
[
351,
64,
880
]
],
[
[
455,
63,
618
],
[
618,
25,
880
]
],
[
[
455,
24,
823
],
[
823,
64,
880
]
],
[
[
455,
25,
384
],
[
384,
25,
880
]
]
] | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
]
] | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Ivabradine
Salmeterol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Ivabradine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may lead to a major life threatening interaction when taken with Ivabradine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may lead to a major life threatening interaction when taken with Ivabradine
Salmeterol may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Ivabradine |
DB11248 | DB11569 | 1,193 | 1,093 | [
"DDInter1965",
"DDInter1003"
] | Zinc gluconate | Ixekizumab | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA. It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and with decreased symptom severity. Although it has been nasally administered for treating the common cold, this route of administration has been associated with some cases of anosmia,,,. Studies show that zinc may be better absorbed in humans in the gluconate form,, however, results from other studies may vary.[A27280, L2082] Interestingly, zinc supplementation has become a critical intervention for treating diarrheal episodes in children. Studies suggest that administration of zinc along with new low osmolarity oral rehydration solutions/salts (oral rehydration solution), may reduce both the duration and severity of diarrhe | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. | Minor | 0 | [
[
[
1193,
23,
1093
]
],
[
[
1193,
62,
66
],
[
66,
24,
1093
]
],
[
[
1193,
23,
270
],
[
270,
63,
1093
]
],
[
[
1193,
62,
1057
],
[
1057,
25,
1093
]
],
[
[
1193,
23,
676
],
[
676,
64,
1093
]
],
[
[
1193,
62,
66
],
[
66,
23,
1114
],
[
1114,
23,
1093
]
],
[
[
1193,
23,
270
],
[
270,
62,
1114
],
[
1114,
23,
1093
]
],
[
[
1193,
62,
1096
],
[
1096,
62,
1031
],
[
1031,
24,
1093
]
],
[
[
1193,
62,
1683
],
[
1683,
62,
1461
],
[
1461,
23,
1093
]
],
[
[
1193,
62,
66
],
[
66,
24,
496
],
[
496,
24,
1093
]
]
] | [
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
]
] | Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ixekizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ixekizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ustekinumab and Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab |
DB11642 | DB11718 | 938 | 927 | [
"DDInter1480",
"DDInter640"
] | Pitolisant | Encorafenib | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pit | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
938,
24,
927
]
],
[
[
938,
62,
112
],
[
112,
23,
927
]
],
[
[
938,
63,
720
],
[
720,
24,
927
]
],
[
[
938,
24,
484
],
[
484,
63,
927
]
],
[
[
938,
24,
1499
],
[
1499,
24,
927
]
],
[
[
938,
25,
1017
],
[
1017,
64,
927
]
],
[
[
938,
64,
39
],
[
39,
25,
927
]
],
[
[
938,
24,
405
],
[
405,
25,
927
]
],
[
[
938,
24,
283
],
[
283,
64,
927
]
],
[
[
938,
63,
760
],
[
760,
25,
927
]
]
] | [
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Pitolisant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Encorafenib"
]
],
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
],
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Pitolisant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Pitolisant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
]
] | Pitolisant may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Pitolisant may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Encorafenib
Pitolisant may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Encorafenib
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Encorafenib
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Encorafenib
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Encorafenib |
DB06800 | DB15305 | 1,159 | 719 | [
"DDInter1188",
"DDInter1603"
] | Methylnaltrexone | Risdiplam | Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008. | Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). It increases systemic SMN protein concentrations by improving the efficiency of _SMN2_ gene transcription. This mechanism of action is similar to its predecessor [nusinersen], the biggest difference being their route of administration: nusinersen requires intrathecal administration, as does the one-time gene therapy [onasemnogene abeparvovec], whereas risdiplam offers the ease of oral bioavailability.[L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).[L15331,L15336] Set to be substantially cheaper than other available SMA therapies, risdiplam appears to provide a novel and relatively accessible treatment option for patients with SMA regardless of severity or type. | Moderate | 1 | [
[
[
1159,
24,
719
]
],
[
[
1159,
21,
28666
],
[
28666,
60,
1645
],
[
1645,
24,
719
]
],
[
[
1159,
24,
785
],
[
785,
63,
1645
],
[
1645,
24,
719
]
]
] | [
[
[
"Methylnaltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risdiplam"
]
],
[
[
"Methylnaltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risdiplam"
]
],
[
[
"Methylnaltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
],
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risdiplam"
]
]
] | Methylnaltrexone (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Metformin (Compound) and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Risdiplam
Methylnaltrexone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib and Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Risdiplam |
DB00773 | DB00851 | 896 | 611 | [
"DDInter702",
"DDInter463"
] | Etoposide | Dacarbazine | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Moderate | 1 | [
[
[
896,
24,
611
]
],
[
[
896,
5,
11555
],
[
11555,
44,
611
]
],
[
[
896,
6,
7950
],
[
7950,
45,
611
]
],
[
[
896,
7,
7669
],
[
7669,
46,
611
]
],
[
[
896,
23,
739
],
[
739,
62,
611
]
],
[
[
896,
23,
646
],
[
646,
23,
611
]
],
[
[
896,
62,
1176
],
[
1176,
23,
611
]
],
[
[
896,
63,
839
],
[
839,
23,
611
]
],
[
[
896,
63,
141
],
[
141,
24,
611
]
],
[
[
896,
24,
850
],
[
850,
63,
611
]
]
] | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etoposide",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Dacarbazine"
]
],
[
[
"Etoposide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Dacarbazine"
]
],
[
[
"Etoposide",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dacarbazine"
]
],
[
[
"Etoposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etoposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cinoxacin"
],
[
"Cinoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etoposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
]
] | Etoposide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dacarbazine (Compound)
Etoposide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dacarbazine (Compound)
Etoposide (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Dacarbazine (Compound)
Etoposide may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine
Etoposide may cause a minor interaction that can limit clinical effects when taken with Cinoxacin and Cinoxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine
Etoposide may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine |
DB00175 | DB00704 | 681 | 267 | [
"DDInter1509",
"DDInter1263"
] | Pravastatin | Naltrexone | Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991. Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group. | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
681,
24,
267
]
],
[
[
681,
6,
4973
],
[
4973,
45,
267
]
],
[
[
681,
21,
28695
],
[
28695,
60,
267
]
],
[
[
681,
24,
522
],
[
522,
24,
267
]
],
[
[
681,
24,
850
],
[
850,
63,
267
]
],
[
[
681,
63,
912
],
[
912,
24,
267
]
],
[
[
681,
1,
1463
],
[
1463,
24,
267
]
],
[
[
681,
35,
467
],
[
467,
24,
267
]
],
[
[
681,
25,
1668
],
[
1668,
24,
267
]
],
[
[
681,
25,
1510
],
[
1510,
64,
267
]
]
] | [
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Pravastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Naltrexone"
]
],
[
[
"Pravastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Naltrexone"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Pravastatin",
"{u} (Compound) resembles {v} (Compound)",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Pravastatin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Pravastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
],
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Pravastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
]
]
] | Pravastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Naltrexone (Compound)
Pravastatin (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Naltrexone (Compound)
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Pravastatin (Compound) resembles Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Pravastatin (Compound) resembles Simvastatin (Compound) and Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Pravastatin may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Pravastatin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Naltrexone |
DB00581 | DB06176 | 355 | 1,342 | [
"DDInter1018",
"DDInter1616"
] | Lactulose | Romidepsin | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipation did not occur until the 1960s and its first clinical use for treating PSE was not until 1966. Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health Organization's List of Essential Medicines as one of the most effective and safe medicines employed in a health system, data regarding its optimal place in therapy is often ambiguous. Especially considering the use of lactulose as a laxative is typically only considered after lifestyle and dietary modifications fail and the | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
355,
24,
1342
]
],
[
[
355,
24,
956
],
[
956,
24,
1342
]
],
[
[
355,
24,
1616
],
[
1616,
63,
1342
]
],
[
[
355,
63,
1010
],
[
1010,
24,
1342
]
],
[
[
355,
23,
286
],
[
286,
63,
1342
]
],
[
[
355,
24,
1493
],
[
1493,
25,
1342
]
],
[
[
355,
63,
695
],
[
695,
25,
1342
]
],
[
[
355,
24,
985
],
[
985,
64,
1342
]
],
[
[
355,
24,
956
],
[
956,
62,
112
],
[
112,
23,
1342
]
],
[
[
355,
24,
485
],
[
485,
23,
1247
],
[
1247,
23,
1342
]
]
] | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Lactulose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Romidepsin"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Romidepsin"
]
]
] | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Romidepsin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Romidepsin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Romidepsin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin |
DB00059 | DB00959 | 1,560 | 1,486 | [
"DDInter1404",
"DDInter1191"
] | Pegaspargase | Methylprednisolone | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Moderate | 1 | [
[
[
1560,
24,
1486
]
],
[
[
1560,
24,
175
],
[
175,
40,
1486
]
],
[
[
1560,
24,
167
],
[
167,
1,
1486
]
],
[
[
1560,
24,
1072
],
[
1072,
23,
1486
]
],
[
[
1560,
24,
127
],
[
127,
24,
1486
]
],
[
[
1560,
24,
1344
],
[
1344,
63,
1486
]
],
[
[
1560,
25,
1101
],
[
1101,
24,
1486
]
],
[
[
1560,
63,
1648
],
[
1648,
24,
1486
]
],
[
[
1560,
25,
962
],
[
962,
64,
1486
]
],
[
[
1560,
24,
593
],
[
593,
64,
1486
]
]
] | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
],
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
]
]
] | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Pegaspargase may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Pegaspargase may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Methylprednisolone
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Methylprednisolone |
DB00405 | DB01081 | 128 | 1,688 | [
"DDInter517",
"DDInter571"
] | Dexbrompheniramine | Diphenoxylate | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II. | Moderate | 1 | [
[
[
128,
24,
1688
]
],
[
[
128,
63,
576
],
[
576,
1,
1688
]
],
[
[
128,
24,
194
],
[
194,
40,
1688
]
],
[
[
128,
24,
1511
],
[
1511,
1,
1688
]
],
[
[
128,
24,
1190
],
[
1190,
63,
1688
]
],
[
[
128,
24,
78
],
[
78,
24,
1688
]
],
[
[
128,
63,
556
],
[
556,
24,
1688
]
],
[
[
128,
74,
1594
],
[
1594,
24,
1688
]
],
[
[
128,
24,
1301
],
[
1301,
74,
1688
]
],
[
[
128,
63,
576
],
[
576,
1,
1413
],
[
1413,
1,
1688
]
]
] | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Diphenoxylate"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
],
[
"Darifenacin",
"{u} (Compound) resembles {v} (Compound)",
"Diphenoxylate"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} (Compound) resembles {v} (Compound)",
"Diphenoxylate"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
],
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} (Compound) resembles {v} (Compound)",
"Diphenoxylate"
]
]
] | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Diphenoxylate (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Diphenoxylate (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate (Compound) resembles Diphenoxylate (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine and Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol and Levacetylmethadol (Compound) resembles Diphenoxylate (Compound) and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Fexofenadine (Compound) and Fexofenadine (Compound) resembles Diphenoxylate (Compound) |
DB00222 | DB00543 | 245 | 87 | [
"DDInter825",
"DDInter82"
] | Glimepiride | Amoxapine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation. | Moderate | 1 | [
[
[
245,
24,
87
]
],
[
[
245,
24,
623
],
[
623,
40,
87
]
],
[
[
245,
24,
867
],
[
867,
1,
87
]
],
[
[
245,
21,
29015
],
[
29015,
60,
87
]
],
[
[
245,
24,
1619
],
[
1619,
63,
87
]
],
[
[
245,
40,
959
],
[
959,
63,
87
]
],
[
[
245,
24,
1152
],
[
1152,
24,
87
]
],
[
[
245,
63,
73
],
[
73,
24,
87
]
],
[
[
245,
64,
600
],
[
600,
24,
87
]
],
[
[
245,
24,
1039
],
[
1039,
64,
87
]
]
] | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
]
],
[
[
"Glimepiride",
"{u} (Compound) causes {v} (Side Effect)",
"Eosinophilia"
],
[
"Eosinophilia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amoxapine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amoxapine"
]
]
] | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Amoxapine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine (Compound) resembles Amoxapine (Compound)
Glimepiride (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Amoxapine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Glimepiride may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Amoxapine |
DB00344 | DB00604 | 1,302 | 1,425 | [
"DDInter1543",
"DDInter385"
] | Protriptyline | Cisapride | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Major | 2 | [
[
[
1302,
25,
1425
]
],
[
[
1302,
24,
1311
],
[
1311,
1,
1425
]
],
[
[
1302,
6,
12523
],
[
12523,
45,
1425
]
],
[
[
1302,
23,
112
],
[
112,
62,
1425
]
],
[
[
1302,
63,
475
],
[
475,
23,
1425
]
],
[
[
1302,
24,
1123
],
[
1123,
63,
1425
]
],
[
[
1302,
24,
19
],
[
19,
24,
1425
]
],
[
[
1302,
24,
971
],
[
971,
64,
1425
]
],
[
[
1302,
24,
79
],
[
79,
25,
1425
]
],
[
[
1302,
63,
600
],
[
600,
25,
1425
]
]
] | [
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} (Compound) resembles {v} (Compound)",
"Cisapride"
]
],
[
[
"Protriptyline",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Cisapride"
]
],
[
[
"Protriptyline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cisapride"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cisapride"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
]
] | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Cisapride (Compound)
Protriptyline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Cisapride (Compound)
Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cisapride
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a minor interaction that can limit clinical effects when taken with Cisapride
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Cisapride
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Cisapride
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may lead to a major life threatening interaction when taken with Cisapride
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Cisapride
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Cisapride |
DB01268 | DB09083 | 1,151 | 880 | [
"DDInter1731",
"DDInter996"
] | Sunitinib | Ivabradine | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects. | Major | 2 | [
[
[
1151,
25,
880
]
],
[
[
1151,
63,
480
],
[
480,
24,
880
]
],
[
[
1151,
24,
159
],
[
159,
63,
880
]
],
[
[
1151,
24,
1040
],
[
1040,
24,
880
]
],
[
[
1151,
64,
1101
],
[
1101,
24,
880
]
],
[
[
1151,
25,
1011
],
[
1011,
24,
880
]
],
[
[
1151,
25,
39
],
[
39,
25,
880
]
],
[
[
1151,
25,
351
],
[
351,
64,
880
]
],
[
[
1151,
24,
774
],
[
774,
25,
880
]
],
[
[
1151,
63,
618
],
[
618,
25,
880
]
]
] | [
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
],
[
"Degarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
]
] | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Sunitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Sunitinib may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Sunitinib may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Ivabradine
Sunitinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Ivabradine
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may lead to a major life threatening interaction when taken with Ivabradine
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may lead to a major life threatening interaction when taken with Ivabradine |
DB00196 | DB00783 | 600 | 1,438 | [
"DDInter743",
"DDInter679"
] | Fluconazole | Estradiol | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vaginal rings, transdermal patches, sprays, gels, and creams.[L11485,L11488,L11491, L11494,L11497,L11500,L11503] When used for oral or IM administration, estradiol is commonly synthesized as a pro-drug ester (such as , , , , and ). Because it has a low oral bioavailability on its own, estradiol is commonly formulated with an ester side-chain. (EE) is a synthetic form of estradiol commonly used as the estrogenic component of most combination oral contraceptive pills (OCPs). Ethinyl estradiol is different from estradiol due to its higher biovailability and increased resistance to metabolism, rendering it more suitable for oral administration. | Moderate | 1 | [
[
[
600,
24,
1438
]
],
[
[
600,
24,
1561
],
[
1561,
40,
1438
]
],
[
[
600,
6,
8374
],
[
8374,
45,
1438
]
],
[
[
600,
21,
28972
],
[
28972,
60,
1438
]
],
[
[
600,
24,
1264
],
[
1264,
62,
1438
]
],
[
[
600,
25,
629
],
[
629,
63,
1438
]
],
[
[
600,
24,
760
],
[
760,
63,
1438
]
],
[
[
600,
25,
126
],
[
126,
24,
1438
]
],
[
[
600,
23,
112
],
[
112,
63,
1438
]
],
[
[
600,
24,
175
],
[
175,
24,
1438
]
]
] | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Estradiol"
]
],
[
[
"Fluconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Urine output increased"
],
[
"Urine output increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Estradiol"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Estradiol"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
]
] | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Estradiol (Compound)
Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Estradiol (Compound)
Fluconazole (Compound) causes Urine output increased (Side Effect) and Urine output increased (Side Effect) is caused by Estradiol (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Estradiol
Fluconazole may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Estradiol
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Estradiol
Fluconazole may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Estradiol
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Estradiol
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Estradiol |
DB00041 | DB00497 | 1,648 | 828 | [
"DDInter38",
"DDInter1366"
] | Aldesleukin | Oxycodone | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950. | Moderate | 1 | [
[
[
1648,
24,
828
]
],
[
[
1648,
24,
421
],
[
421,
1,
828
]
],
[
[
1648,
24,
267
],
[
267,
64,
828
]
],
[
[
1648,
24,
560
],
[
560,
40,
828
]
],
[
[
1648,
24,
849
],
[
849,
63,
828
]
],
[
[
1648,
25,
908
],
[
908,
63,
828
]
],
[
[
1648,
24,
1614
],
[
1614,
24,
828
]
],
[
[
1648,
64,
1057
],
[
1057,
24,
828
]
],
[
[
1648,
63,
1184
],
[
1184,
24,
828
]
],
[
[
1648,
25,
581
],
[
581,
24,
828
]
]
] | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxycodone"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
],
[
"Oxymorphone",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
]
] | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Oxycodone (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may lead to a major life threatening interaction when taken with Oxycodone
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Oxymorphone and Oxymorphone (Compound) resembles Oxycodone (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Aldesleukin may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Aldesleukin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Aldesleukin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone |
DB00241 | DB06605 | 288 | 1,409 | [
"DDInter257",
"DDInter108"
] | Butalbital | Apixaban | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Moderate | 1 | [
[
[
288,
24,
1409
]
],
[
[
288,
24,
1670
],
[
1670,
63,
1409
]
],
[
[
288,
24,
723
],
[
723,
24,
1409
]
],
[
[
288,
1,
536
],
[
536,
24,
1409
]
],
[
[
288,
40,
1023
],
[
1023,
24,
1409
]
],
[
[
288,
25,
765
],
[
765,
24,
1409
]
],
[
[
288,
23,
1101
],
[
1101,
24,
1409
]
],
[
[
288,
24,
39
],
[
39,
25,
1409
]
],
[
[
288,
24,
405
],
[
405,
64,
1409
]
],
[
[
288,
25,
126
],
[
126,
25,
1409
]
]
] | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
],
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Butalbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Butalbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Butalbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
]
] | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Butalbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Butalbital may lead to a major life threatening interaction when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Butalbital may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Apixaban
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Apixaban
Butalbital may lead to a major life threatening interaction when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Apixaban |
DB06772 | DB12010 | 310 | 214 | [
"DDInter259",
"DDInter785"
] | Cabazitaxel | Fostamatinib | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
310,
24,
214
]
],
[
[
310,
25,
976
],
[
976,
24,
214
]
],
[
[
310,
63,
723
],
[
723,
24,
214
]
],
[
[
310,
62,
307
],
[
307,
24,
214
]
],
[
[
310,
24,
1362
],
[
1362,
24,
214
]
],
[
[
310,
24,
179
],
[
179,
63,
214
]
],
[
[
310,
25,
676
],
[
676,
63,
214
]
],
[
[
310,
63,
609
],
[
609,
25,
214
]
],
[
[
310,
25,
1292
],
[
1292,
25,
214
]
],
[
[
310,
64,
695
],
[
695,
25,
214
]
]
] | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
],
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
]
] | Cabazitaxel may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cabazitaxel may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl and Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cabazitaxel may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Fostamatinib
Cabazitaxel may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Fostamatinib
Cabazitaxel may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Fostamatinib |
DB00748 | DB11732 | 662 | 1,097 | [
"DDInter297",
"DDInter1027"
] | Carbinoxamine | Lasmiditan | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks. | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety. Their use is not devoid of concerns, however, and their vasoconstrictive activity can lead to blood pressure lability and other cardiovascular side effects - for this reason, these medications are less suitable for use in patients with pre-existing cardiovascular disorders. Triptans abort migraines via action at several serotonin receptors, including 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors, and activity at the 5-HT<sub>1B</sub> receptor has been specifically implicated in their vasoconstrictive activity.[A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for the adverse effect profile of its predecessors - in other words, lasmiditan’s selectivity allows for the successful termination of migraines without causing vasoconstriction.[A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class of anti-migraine medications in which lasmiditan is the first and only member: the neurally-acting anti-migraine medications (NAAMAs).[A187322,A187307] | Moderate | 1 | [
[
[
662,
24,
1097
]
],
[
[
662,
63,
701
],
[
701,
24,
1097
]
],
[
[
662,
35,
832
],
[
832,
24,
1097
]
],
[
[
662,
24,
1311
],
[
1311,
24,
1097
]
],
[
[
662,
24,
1053
],
[
1053,
25,
1097
]
],
[
[
662,
63,
506
],
[
506,
25,
1097
]
],
[
[
662,
63,
701
],
[
701,
24,
1614
],
[
1614,
24,
1097
]
],
[
[
662,
63,
1614
],
[
1614,
63,
701
],
[
701,
24,
1097
]
],
[
[
662,
35,
832
],
[
832,
63,
701
],
[
701,
24,
1097
]
],
[
[
662,
63,
475
],
[
475,
24,
971
],
[
971,
63,
1097
]
]
] | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lasmiditan"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lasmiditan"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
]
] | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Carbinoxamine (Compound) resembles Tripelennamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Lasmiditan
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may lead to a major life threatening interaction when taken with Lasmiditan
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Carbinoxamine (Compound) resembles Tripelennamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan |
DB00862 | DB01041 | 1,005 | 770 | [
"DDInter1918",
"DDInter1789"
] | Vardenafil | Thalidomide | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the synthesis of cGMP in the smooth muscle cells of the corpus cavernosum. PDE5 inhibitors, such as vardenafil, inhibit the degradation of cGMP and allow increased blood flow into the penis, resulting in an erection.[A258303,L45563,L45568]. Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil. The FDA approved the use of v | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Moderate | 1 | [
[
[
1005,
24,
770
]
],
[
[
1005,
6,
7524
],
[
7524,
45,
770
]
],
[
[
1005,
21,
29425
],
[
29425,
60,
770
]
],
[
[
1005,
25,
609
],
[
609,
63,
770
]
],
[
[
1005,
63,
1557
],
[
1557,
24,
770
]
],
[
[
1005,
24,
1228
],
[
1228,
63,
770
]
],
[
[
1005,
24,
1559
],
[
1559,
24,
770
]
],
[
[
1005,
64,
1166
],
[
1166,
24,
770
]
],
[
[
1005,
63,
322
],
[
322,
25,
770
]
],
[
[
1005,
24,
1377
],
[
1377,
64,
770
]
]
] | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Vardenafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Vardenafil",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial ischaemia"
],
[
"Myocardial ischaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Astemizole"
],
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
],
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
]
] | Vardenafil (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Vardenafil (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is caused by Thalidomide (Compound)
Vardenafil may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Vardenafil may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Thalidomide
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Thalidomide |
DB00928 | DB10583 | 1,426 | 949 | [
"DDInter148",
"DDInter415"
] | Azacitidine | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and inhibiting protein and DNA synthesis. The other one is through the inhibition of DNA methyltransferase, impairing DNA methylation. Due to its anti-neoplastic activity and its ability to inhibit methylation in replicating DNA, azacytidine has been used mainly used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), two types of cancer characterized by the presence of aberrant DNA methylation.[ | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium sulfate filtration and precipation. | Moderate | 1 | [
[
[
1426,
24,
949
]
],
[
[
1426,
25,
1377
],
[
1377,
24,
949
]
],
[
[
1426,
63,
58
],
[
58,
24,
949
]
],
[
[
1426,
1,
1488
],
[
1488,
24,
949
]
],
[
[
1426,
25,
1259
],
[
1259,
63,
949
]
],
[
[
1426,
24,
1683
],
[
1683,
24,
949
]
],
[
[
1426,
64,
1066
],
[
1066,
24,
949
]
],
[
[
1426,
24,
270
],
[
270,
63,
949
]
],
[
[
1426,
40,
372
],
[
372,
24,
949
]
],
[
[
1426,
25,
1377
],
[
1377,
64,
550
],
[
550,
24,
949
]
]
] | [
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Azacitidine",
"{u} (Compound) resembles {v} (Compound)",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Azacitidine",
"{u} (Compound) resembles {v} (Compound)",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab"
],
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
]
] | Azacitidine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Azacitidine (Compound) resembles Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Azacitidine may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Azacitidine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Azacitidine (Compound) resembles Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Azacitidine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) |
DB00489 | DB12245 | 17 | 823 | [
"DDInter1704",
"DDInter1863"
] | Sotalol | Triclabendazole | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376] | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] | Major | 2 | [
[
[
17,
25,
823
]
],
[
[
17,
23,
112
],
[
112,
23,
823
]
],
[
[
17,
64,
1010
],
[
1010,
24,
823
]
],
[
[
17,
24,
28
],
[
28,
24,
823
]
],
[
[
17,
25,
77
],
[
77,
24,
823
]
],
[
[
17,
25,
1619
],
[
1619,
63,
823
]
],
[
[
17,
36,
1674
],
[
1674,
24,
823
]
],
[
[
17,
35,
1148
],
[
1148,
24,
823
]
],
[
[
17,
25,
868
],
[
868,
25,
823
]
],
[
[
17,
64,
702
],
[
702,
25,
823
]
]
] | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Sotalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Sotalol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Sotalol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
]
] | Sotalol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Sotalol may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Sotalol may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Sotalol may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Sotalol (Compound) resembles Orciprenaline (Compound) and Sotalol may lead to a major life threatening interaction when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Sotalol (Compound) resembles Isoprenaline (Compound) and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Sotalol may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Triclabendazole
Sotalol may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Triclabendazole |
DB00341 | DB00980 | 1,242 | 969 | [
"DDInter343",
"DDInter1564"
] | Cetirizine | Ramelteon | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allergic rhinitis_. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals. Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects. Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
1242,
24,
969
]
],
[
[
1242,
21,
28714
],
[
28714,
60,
969
]
],
[
[
1242,
24,
100
],
[
100,
24,
969
]
],
[
[
1242,
24,
649
],
[
649,
63,
969
]
],
[
[
1242,
74,
701
],
[
701,
24,
969
]
],
[
[
1242,
63,
1648
],
[
1648,
24,
969
]
],
[
[
1242,
63,
475
],
[
475,
25,
969
]
],
[
[
1242,
21,
28714
],
[
28714,
60,
1144
],
[
1144,
24,
969
]
],
[
[
1242,
24,
100
],
[
100,
6,
8374
],
[
8374,
45,
969
]
],
[
[
1242,
24,
832
],
[
832,
24,
100
],
[
100,
24,
969
]
]
] | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramelteon"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
]
] | Cetirizine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Ramelteon (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Cetirizine (Compound) resembles Clemastine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Ramelteon
Cetirizine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ramelteon (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon |
DB00983 | DB06699 | 480 | 774 | [
"DDInter776",
"DDInter493"
] | Formoterol | Degarelix | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. | Moderate | 1 | [
[
[
480,
24,
774
]
],
[
[
480,
63,
521
],
[
521,
1,
774
]
],
[
[
480,
21,
29232
],
[
29232,
60,
774
]
],
[
[
480,
63,
888
],
[
888,
24,
774
]
],
[
[
480,
24,
956
],
[
956,
24,
774
]
],
[
[
480,
24,
484
],
[
484,
63,
774
]
],
[
[
480,
74,
1052
],
[
1052,
24,
774
]
],
[
[
480,
24,
33
],
[
33,
25,
774
]
],
[
[
480,
24,
880
],
[
880,
64,
774
]
],
[
[
480,
63,
1176
],
[
1176,
25,
774
]
]
] | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
]
],
[
[
"Formoterol",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Degarelix"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Formoterol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
],
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
]
] | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Formoterol (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Formoterol (Compound) resembles Ritodrine (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may lead to a major life threatening interaction when taken with Degarelix
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine and Ivabradine may lead to a major life threatening interaction when taken with Degarelix
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may lead to a major life threatening interaction when taken with Degarelix |
DB00372 | DB00612 | 999 | 1,121 | [
"DDInter1793",
"DDInter216"
] | Thiethylperazine | Bisoprolol | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as [Carvedilol] and [Labetalol]. It may be used alone or in combination with other drugs to manage hypertension and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity. | Moderate | 1 | [
[
[
999,
24,
1121
]
],
[
[
999,
24,
819
],
[
819,
40,
1121
]
],
[
[
999,
63,
88
],
[
88,
40,
1121
]
],
[
[
999,
62,
417
],
[
417,
23,
1121
]
],
[
[
999,
23,
1283
],
[
1283,
62,
1121
]
],
[
[
999,
24,
433
],
[
433,
63,
1121
]
],
[
[
999,
25,
497
],
[
497,
63,
1121
]
],
[
[
999,
24,
19
],
[
19,
24,
1121
]
],
[
[
999,
63,
352
],
[
352,
24,
1121
]
],
[
[
999,
24,
819
],
[
819,
40,
236
],
[
236,
40,
1121
]
]
] | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bisoprolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bisoprolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Esmolol"
],
[
"Esmolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
]
]
] | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Bisoprolol (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Bisoprolol (Compound)
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Bisoprolol
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Bisoprolol
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Thiethylperazine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Esmolol (Compound) and Esmolol (Compound) resembles Bisoprolol (Compound) |
DB06203 | DB14730 | 1,002 | 1,412 | [
"DDInter51",
"DDInter264"
] | Alogliptin | Calaspargase pegol | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , . Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL . The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], . Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) . | Moderate | 1 | [
[
[
1002,
24,
1412
]
],
[
[
1002,
63,
1144
],
[
1144,
24,
1412
]
],
[
[
1002,
24,
850
],
[
850,
24,
1412
]
],
[
[
1002,
1,
1281
],
[
1281,
24,
1412
]
],
[
[
1002,
64,
1101
],
[
1101,
25,
1412
]
],
[
[
1002,
63,
1144
],
[
1144,
24,
159
],
[
159,
24,
1412
]
],
[
[
1002,
24,
850
],
[
850,
24,
250
],
[
250,
24,
1412
]
],
[
[
1002,
24,
1019
],
[
1019,
63,
1439
],
[
1439,
24,
1412
]
],
[
[
1002,
63,
1411
],
[
1411,
62,
1347
],
[
1347,
24,
1412
]
],
[
[
1002,
1,
1281
],
[
1281,
63,
1144
],
[
1144,
24,
1412
]
]
] | [
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Alogliptin",
"{u} (Compound) resembles {v} (Compound)",
"Linagliptin"
],
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Alogliptin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
],
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Alogliptin",
"{u} (Compound) resembles {v} (Compound)",
"Linagliptin"
],
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
]
] | Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Alogliptin (Compound) resembles Linagliptin (Compound) and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Alogliptin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Calaspargase pegol
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Alogliptin (Compound) resembles Linagliptin (Compound) and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol |
DB00370 | DB00400 | 1,251 | 353 | [
"DDInter1230",
"DDInter843"
] | Mirtazapine | Griseofulvin | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery. | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Moderate | 1 | [
[
[
1251,
24,
353
]
],
[
[
1251,
6,
8374
],
[
8374,
45,
353
]
],
[
[
1251,
21,
29093
],
[
29093,
60,
353
]
],
[
[
1251,
63,
1101
],
[
1101,
23,
353
]
],
[
[
1251,
24,
1297
],
[
1297,
63,
353
]
],
[
[
1251,
25,
868
],
[
868,
63,
353
]
],
[
[
1251,
24,
79
],
[
79,
24,
353
]
],
[
[
1251,
63,
1010
],
[
1010,
24,
353
]
],
[
[
1251,
6,
8374
],
[
8374,
45,
168
],
[
168,
23,
353
]
],
[
[
1251,
21,
29093
],
[
29093,
60,
168
],
[
168,
23,
353
]
]
] | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Griseofulvin"
]
],
[
[
"Mirtazapine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Griseofulvin"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Griseofulvin"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Griseofulvin"
]
],
[
[
"Mirtazapine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Griseofulvin"
]
]
] | Mirtazapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Griseofulvin (Compound)
Mirtazapine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Griseofulvin (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Mirtazapine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Mirtazapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Mirtazapine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Griseofulvin |
DB01004 | DB08904 | 563 | 375 | [
"DDInter806",
"DDInter342"
] | Ganciclovir | Certolizumab pegol | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Major | 2 | [
[
[
563,
25,
375
]
],
[
[
563,
63,
10
],
[
10,
24,
375
]
],
[
[
563,
63,
552
],
[
552,
25,
375
]
],
[
[
563,
24,
328
],
[
328,
25,
375
]
],
[
[
563,
24,
1480
],
[
1480,
64,
375
]
],
[
[
563,
64,
1064
],
[
1064,
25,
375
]
],
[
[
563,
1,
248
],
[
248,
25,
375
]
],
[
[
563,
25,
1292
],
[
1292,
25,
375
]
],
[
[
563,
63,
10
],
[
10,
24,
231
],
[
231,
24,
375
]
],
[
[
563,
63,
599
],
[
599,
24,
200
],
[
200,
63,
375
]
]
] | [
[
[
"Ganciclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Ganciclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Ganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Ganciclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
],
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
]
] | Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Certolizumab pegol
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may lead to a major life threatening interaction when taken with Certolizumab pegol
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may lead to a major life threatening interaction when taken with Certolizumab pegol
Ganciclovir may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Certolizumab pegol
Ganciclovir (Compound) resembles Valganciclovir (Compound) and Val
Ganciclovir may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Certolizumab pegol
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol |
DB00641 | DB11986 | 467 | 484 | [
"DDInter1675",
"DDInter648"
] | Simvastatin | Entrectinib | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Moderate | 1 | [
[
[
467,
24,
484
]
],
[
[
467,
24,
112
],
[
112,
23,
484
]
],
[
[
467,
24,
466
],
[
466,
62,
484
]
],
[
[
467,
24,
1072
],
[
1072,
24,
484
]
],
[
[
467,
63,
322
],
[
322,
24,
484
]
],
[
[
467,
24,
242
],
[
242,
63,
484
]
],
[
[
467,
64,
376
],
[
376,
24,
484
]
],
[
[
467,
74,
1463
],
[
1463,
24,
484
]
],
[
[
467,
62,
1428
],
[
1428,
24,
484
]
],
[
[
467,
25,
1554
],
[
1554,
24,
484
]
]
] | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amlodipine"
],
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Simvastatin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Colchicine"
],
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
]
] | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Simvastatin may lead to a major life threatening interaction when taken with Amlodipine and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Simvastatin (Compound) resembles Lovastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Simvastatin may cause a minor interaction that can limit clinical effects when taken with Isradipine and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Simvastatin may lead to a major life threatening interaction when taken with Colchicine and Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib |
DB00372 | DB11632 | 999 | 580 | [
"DDInter1793",
"DDInter1343"
] | Thiethylperazine | Opicapone | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management of these symptoms through the use of a dopamine agonist, a monoamine oxidase B inhibitor (selegiline, rasagiline), a _catechol-O-methyl transferase (COMT)_ inhibitor, or amantadine, or using a modified-release formulation of levodopa. Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations. Opicapone was approved for use by the European Commission in June 2016 and the FDA in April 2020. It is marketed under the brand name Ongentys as once-daily oral capsules. Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase inhibitors. | Moderate | 1 | [
[
[
999,
24,
580
]
],
[
[
999,
24,
401
],
[
401,
24,
580
]
],
[
[
999,
63,
475
],
[
475,
24,
580
]
],
[
[
999,
25,
1311
],
[
1311,
24,
580
]
],
[
[
999,
24,
1053
],
[
1053,
25,
580
]
],
[
[
999,
24,
401
],
[
401,
63,
104
],
[
104,
24,
580
]
],
[
[
999,
24,
1233
],
[
1233,
24,
104
],
[
104,
24,
580
]
],
[
[
999,
63,
475
],
[
475,
24,
104
],
[
104,
24,
580
]
],
[
[
999,
25,
1311
],
[
1311,
64,
104
],
[
104,
24,
580
]
],
[
[
999,
25,
1311
],
[
1311,
24,
830
],
[
830,
24,
580
]
]
] | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opicapone"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
]
] | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Opicapone
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone |
DB08895 | DB10989 | 976 | 496 | [
"DDInter1825",
"DDInter858"
] | Tofacitinib | Hepatitis A Vaccine | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection against the disease caused by infection with this virus.[A199185,L12756] In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries. | Moderate | 1 | [
[
[
976,
24,
496
]
],
[
[
976,
25,
1093
],
[
1093,
63,
496
]
],
[
[
976,
64,
4
],
[
4,
24,
496
]
],
[
[
976,
25,
951
],
[
951,
24,
496
]
],
[
[
976,
25,
1093
],
[
1093,
63,
4
],
[
4,
24,
496
]
],
[
[
976,
64,
4
],
[
4,
24,
1093
],
[
1093,
63,
496
]
],
[
[
976,
64,
850
],
[
850,
63,
4
],
[
4,
24,
496
]
],
[
[
976,
64,
77
],
[
77,
24,
4
],
[
4,
24,
496
]
],
[
[
976,
25,
270
],
[
270,
63,
1093
],
[
1093,
63,
496
]
],
[
[
976,
64,
908
],
[
908,
25,
1093
],
[
1093,
63,
496
]
]
] | [
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
]
] | Tofacitinib may lead to a major life threatening interaction when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Tofacitinib may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Tofacitinib may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Tofacitinib may lead to a major life threatening interaction when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Tofacitinib may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Tofacitinib may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Tofacitinib may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Tofacitinib may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Tofacitinib may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine |
DB00512 | DB01050 | 91 | 848 | [
"DDInter1916",
"DDInter900"
] | Vancomycin | Ibuprofen | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains. Such an oral liquid formulation is expected to make _Clostridium difficile_ associated diarrhea therapy more accessible in comparison to previously available specialty compounding products. | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer. | Moderate | 1 | [
[
[
91,
24,
848
]
],
[
[
91,
6,
10612
],
[
10612,
45,
848
]
],
[
[
91,
21,
28942
],
[
28942,
60,
848
]
],
[
[
91,
63,
831
],
[
831,
24,
848
]
],
[
[
91,
24,
242
],
[
242,
63,
848
]
],
[
[
91,
24,
59
],
[
59,
24,
848
]
],
[
[
91,
25,
1552
],
[
1552,
64,
848
]
],
[
[
91,
25,
629
],
[
629,
25,
848
]
],
[
[
91,
63,
886
],
[
886,
25,
848
]
],
[
[
91,
24,
663
],
[
663,
25,
848
]
]
] | [
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Vancomycin",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Vancomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis bullous"
],
[
"Dermatitis bullous",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
],
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Vancomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
],
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
]
],
[
[
"Vancomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
],
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
]
]
] | Vancomycin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Ibuprofen (Compound)
Vancomycin (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Ibuprofen (Compound)
Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Etodolac and Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Vancomycin may lead to a major life threatening interaction when taken with Ioversol and Ioversol may lead to a major life threatening interaction when taken with Ibuprofen
Vancomycin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Ibuprofen
Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac may lead to a major life threatening interaction when taken with Ibuprofen
Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Ibuprofen |
DB00794 | DB01285 | 759 | 708 | [
"DDInter1521",
"DDInter445"
] | Primidone | Corticotropin | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
759,
24,
708
]
],
[
[
759,
64,
126
],
[
126,
24,
708
]
],
[
[
759,
1,
697
],
[
697,
24,
708
]
],
[
[
759,
24,
1450
],
[
1450,
63,
708
]
],
[
[
759,
63,
1184
],
[
1184,
24,
708
]
],
[
[
759,
24,
1130
],
[
1130,
24,
708
]
],
[
[
759,
63,
1057
],
[
1057,
25,
708
]
],
[
[
759,
24,
593
],
[
593,
25,
708
]
],
[
[
759,
24,
375
],
[
375,
64,
708
]
],
[
[
759,
25,
976
],
[
976,
64,
708
]
]
] | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Corticotropin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Corticotropin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Corticotropin"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Corticotropin"
]
]
] | Primidone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Primidone (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Corticotropin
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Corticotropin
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Corticotropin
Primidone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Corticotropin |
DB00963 | DB01276 | 1,263 | 123 | [
"DDInter241",
"DDInter706"
] | Bromfenac | Exenatide | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available. | Moderate | 1 | [
[
[
1263,
24,
123
]
],
[
[
1263,
63,
1573
],
[
1573,
24,
123
]
],
[
[
1263,
24,
222
],
[
222,
24,
123
]
],
[
[
1263,
24,
850
],
[
850,
63,
123
]
],
[
[
1263,
64,
126
],
[
126,
24,
123
]
],
[
[
1263,
25,
4
],
[
4,
63,
123
]
],
[
[
1263,
1,
935
],
[
935,
24,
123
]
],
[
[
1263,
63,
1573
],
[
1573,
63,
1252
],
[
1252,
23,
123
]
],
[
[
1263,
63,
1560
],
[
1560,
24,
1463
],
[
1463,
23,
123
]
],
[
[
1263,
24,
222
],
[
222,
63,
532
],
[
532,
24,
123
]
]
] | [
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bromfenac",
"{u} (Compound) resembles {v} (Compound)",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
],
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
]
] | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bromfenac may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bromfenac may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bromfenac (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide |
DB00620 | DB08868 | 175 | 1,011 | [
"DDInter1855",
"DDInter737"
] | Triamcinolone | Fingolimod | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Major | 2 | [
[
[
175,
25,
1011
]
],
[
[
175,
5,
11594
],
[
11594,
44,
1011
]
],
[
[
175,
6,
8374
],
[
8374,
45,
1011
]
],
[
[
175,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
175,
24,
61
],
[
61,
24,
1011
]
],
[
[
175,
63,
751
],
[
751,
24,
1011
]
],
[
[
175,
25,
915
],
[
915,
24,
1011
]
],
[
[
175,
24,
748
],
[
748,
63,
1011
]
],
[
[
175,
23,
480
],
[
480,
24,
1011
]
],
[
[
175,
23,
1032
],
[
1032,
63,
1011
]
]
] | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Triamcinolone",
"{u} (Compound) treats {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u} (Disease) is treated by {v} (Compound)",
"Fingolimod"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fingolimod"
]
],
[
[
"Triamcinolone",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac arrest"
],
[
"Cardiac arrest",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fingolimod"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
],
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
],
[
"Pyridostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
],
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
]
] | Triamcinolone (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Fingolimod (Compound)
Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Triamcinolone (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Triamcinolone may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod |
DB00586 | DB08870 | 1,512 | 850 | [
"DDInter537",
"DDInter228"
] | Diclofenac | Brentuximab vedotin | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease. | Moderate | 1 | [
[
[
1512,
24,
850
]
],
[
[
1512,
35,
1338
],
[
1338,
24,
850
]
],
[
[
1512,
24,
267
],
[
267,
24,
850
]
],
[
[
1512,
63,
443
],
[
443,
24,
850
]
],
[
[
1512,
24,
1033
],
[
1033,
63,
850
]
],
[
[
1512,
64,
886
],
[
886,
24,
850
]
],
[
[
1512,
25,
1468
],
[
1468,
63,
850
]
],
[
[
1512,
23,
122
],
[
122,
24,
850
]
],
[
[
1512,
25,
39
],
[
39,
24,
850
]
],
[
[
1512,
25,
1510
],
[
1510,
64,
850
]
]
] | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
],
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Spironolactone"
],
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketorolac"
],
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
]
] | Diclofenac (Compound) resembles Meclofenamic acid (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Diclofenac may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Diclofenac may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Verapamil and Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Diclofenac may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Diclofenac may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin |
DB08873 | DB09039 | 74 | 1,670 | [
"DDInter221",
"DDInter629"
] | Boceprevir | Eliglustat | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634] | Major | 2 | [
[
[
74,
25,
1670
]
],
[
[
74,
25,
1135
],
[
1135,
62,
1670
]
],
[
[
74,
64,
1409
],
[
1409,
24,
1670
]
],
[
[
74,
24,
1499
],
[
1499,
63,
1670
]
],
[
[
74,
25,
124
],
[
124,
63,
1670
]
],
[
[
74,
63,
1220
],
[
1220,
24,
1670
]
],
[
[
74,
24,
868
],
[
868,
24,
1670
]
],
[
[
74,
63,
86
],
[
86,
25,
1670
]
],
[
[
74,
62,
1374
],
[
1374,
25,
1670
]
],
[
[
74,
25,
283
],
[
283,
64,
1670
]
]
] | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eliglustat"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Boceprevir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
]
] | Boceprevir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Boceprevir may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Boceprevir may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may lead to a major life threatening interaction when taken with Eliglustat
Boceprevir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may lead to a major life threatening interaction when taken with Eliglustat
Boceprevir may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Eliglustat |
DB10315 | DB11760 | 1,137 | 119 | [
"DDInter1127",
"DDInter1742"
] | Measles virus vaccine live attenuated | Talazoparib | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada in September 2020. Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306] | Major | 2 | [
[
[
1137,
25,
119
]
],
[
[
1137,
64,
66
],
[
66,
24,
119
]
],
[
[
1137,
25,
351
],
[
351,
24,
119
]
],
[
[
1137,
25,
1619
],
[
1619,
63,
119
]
],
[
[
1137,
64,
1011
],
[
1011,
25,
119
]
],
[
[
1137,
25,
676
],
[
676,
64,
119
]
],
[
[
1137,
64,
66
],
[
66,
24,
1129
],
[
1129,
63,
119
]
],
[
[
1137,
64,
599
],
[
599,
24,
66
],
[
66,
24,
119
]
],
[
[
1137,
64,
713
],
[
713,
63,
66
],
[
66,
24,
119
]
],
[
[
1137,
25,
351
],
[
351,
63,
66
],
[
66,
24,
119
]
]
] | [
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
],
[
"Human adenovirus e serotype 4 strain cl-68578 antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
]
] | Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib |
DB00069 | DB01030 | 367 | 869 | [
"DDInter946",
"DDInter1835"
] | Interferon alfacon-1 | Topotecan | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon- | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
367,
24,
869
]
],
[
[
367,
24,
310
],
[
310,
63,
869
]
],
[
[
367,
24,
482
],
[
482,
24,
869
]
],
[
[
367,
25,
1064
],
[
1064,
24,
869
]
],
[
[
367,
63,
1451
],
[
1451,
24,
869
]
],
[
[
367,
25,
72
],
[
72,
63,
869
]
],
[
[
367,
64,
1648
],
[
1648,
24,
869
]
],
[
[
367,
23,
450
],
[
450,
24,
869
]
],
[
[
367,
63,
1057
],
[
1057,
25,
869
]
],
[
[
367,
25,
676
],
[
676,
64,
869
]
]
] | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfa-n1"
],
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eltrombopag"
],
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
]
]
] | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Interferon alfacon-1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Topotecan
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Topotecan |
DB00470 | DB01114 | 530 | 272 | [
"DDInter601",
"DDInter362"
] | Dronabinol | Chlorpheniramine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
530,
24,
272
]
],
[
[
530,
24,
358
],
[
358,
63,
272
]
],
[
[
530,
63,
128
],
[
128,
24,
272
]
],
[
[
530,
6,
8374
],
[
8374,
45,
272
]
],
[
[
530,
21,
28705
],
[
28705,
60,
272
]
],
[
[
530,
24,
1565
],
[
1565,
24,
272
]
],
[
[
530,
25,
1301
],
[
1301,
63,
272
]
],
[
[
530,
1,
1614
],
[
1614,
24,
272
]
],
[
[
530,
64,
534
],
[
534,
24,
272
]
],
[
[
530,
25,
675
],
[
675,
25,
272
]
]
] | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Chlorpheniramine"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Drowsiness"
],
[
"Drowsiness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Chlorpheniramine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
],
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Dronabinol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Dronabinol",
"{u} (Compound) resembles {v} (Compound)",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Dronabinol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Dronabinol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlorpheniramine"
]
]
] | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Chlorpheniramine (Compound)
Dronabinol (Compound) causes Drowsiness (Side Effect) and Drowsiness (Side Effect) is caused by Chlorpheniramine (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Dronabinol may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Dronabinol may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Dronabinol may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Chlorpheniramine |
DB00327 | DB00758 | 421 | 1,347 | [
"DDInter890",
"DDInter413"
] | Hydromorphone | Clopidogrel | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it presents a very high potency and comparable side effect profile to the parent compound. Even though hydromorphone does not present a 6-hydroxyl group, it is categorized under the family of phenanthrenes and it is considered a chemical under the schedule II (medical purposes with high addiction potential). The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984. | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997. | Moderate | 1 | [
[
[
421,
24,
1347
]
],
[
[
421,
6,
8374
],
[
8374,
45,
1347
]
],
[
[
421,
21,
29402
],
[
29402,
60,
1347
]
],
[
[
421,
24,
578
],
[
578,
63,
1347
]
],
[
[
421,
1,
560
],
[
560,
63,
1347
]
],
[
[
421,
1,
828
],
[
828,
24,
1347
]
],
[
[
421,
24,
121
],
[
121,
24,
1347
]
],
[
[
421,
64,
475
],
[
475,
24,
1347
]
],
[
[
421,
25,
593
],
[
593,
63,
1347
]
],
[
[
421,
24,
543
],
[
543,
64,
1347
]
]
] | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Hydromorphone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clopidogrel"
]
],
[
[
"Hydromorphone",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatobiliary disease"
],
[
"Hepatobiliary disease",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clopidogrel"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Oxymorphone"
],
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Hydromorphone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Hydromorphone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
]
]
] | Hydromorphone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clopidogrel (Compound)
Hydromorphone (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Clopidogrel (Compound)
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Hydromorphone (Compound) resembles Oxymorphone (Compound) and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Hydromorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Hydromorphone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Hydromorphone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may lead to a major life threatening interaction when taken with Clopidogrel |
DB00472 | DB12015 | 758 | 1,033 | [
"DDInter758",
"DDInter53"
] | Fluoxetine | Alpelisib | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy. | Moderate | 1 | [
[
[
758,
24,
1033
]
],
[
[
758,
24,
1254
],
[
1254,
24,
1033
]
],
[
[
758,
63,
322
],
[
322,
24,
1033
]
],
[
[
758,
25,
985
],
[
985,
24,
1033
]
],
[
[
758,
25,
982
],
[
982,
63,
1033
]
],
[
[
758,
24,
1619
],
[
1619,
63,
1033
]
],
[
[
758,
24,
498
],
[
498,
25,
1033
]
],
[
[
758,
24,
1254
],
[
1254,
24,
154
],
[
154,
24,
1033
]
],
[
[
758,
63,
322
],
[
322,
64,
576
],
[
576,
24,
1033
]
],
[
[
758,
24,
1342
],
[
1342,
64,
576
],
[
576,
24,
1033
]
]
] | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alpelisib"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
]
] | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Fluoxetine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Fluoxetine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban and Edoxaban may lead to a major life threatening interaction when taken with Alpelisib
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib |
DB00863 | DB04868 | 1,194 | 478 | [
"DDInter1568",
"DDInter1293"
] | Ranitidine | Nilotinib | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818] | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Moderate | 1 | [
[
[
1194,
24,
478
]
],
[
[
1194,
23,
1468
],
[
1468,
63,
478
]
],
[
[
1194,
6,
4973
],
[
4973,
45,
478
]
],
[
[
1194,
21,
28762
],
[
28762,
60,
478
]
],
[
[
1194,
23,
809
],
[
809,
62,
478
]
],
[
[
1194,
63,
479
],
[
479,
23,
478
]
],
[
[
1194,
24,
1040
],
[
1040,
63,
478
]
],
[
[
1194,
63,
126
],
[
126,
24,
478
]
],
[
[
1194,
40,
1127
],
[
1127,
24,
478
]
],
[
[
1194,
62,
1512
],
[
1512,
24,
478
]
]
] | [
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Ranitidine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Ranitidine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Raltegravir"
],
[
"Raltegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Ranitidine",
"{u} (Compound) resembles {v} (Compound)",
"Nizatidine"
],
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
]
] | Ranitidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ranitidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Ranitidine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nilotinib (Compound)
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Raltegravir and Raltegravir may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ranitidine (Compound) resembles Nizatidine (Compound) and Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib |
DB00445 | DB01076 | 322 | 700 | [
"DDInter655",
"DDInter133"
] | Epirubicin | Atorvastatin | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal side effects and long term benefits, has resulted in wide use of this medication in North America.[A181087, A181406] Atorvastatin and other statins including [lovastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [simvastatin] are considered first-line treatment options for dyslipidemia.[A181087, A181406] The increasing use of this class of drugs is largely attributed to the rise in cardiovascular diseases (CVD) (such as heart attack, atherosclerosis, angina, peripheral artery disease, and stroke) in many countries. An elevated cholesterol level (elevated low-density lipoprotein (LDL) levels in particular) is a significant risk factor for the development of CVD.[A181087,A181553] Several landmark studies demonstrate that the use of statins is associated with both a reduction in LDL levels and CVD risk.[A181090,A181093,A181096,A181427,A181475,A181538] Statins were shown to reduce the incidences of all-cause mortality, including fatal and non-fatal CVD, as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Some evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within five years) statin use leads to a 20%-22% relative reduction in the number of major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996. It is a pentasubstituted pyrrole formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound. Unlike other members of the statin group, atorvastatin is an active compound and therefore does not require activation. | Moderate | 1 | [
[
[
322,
24,
700
]
],
[
[
322,
24,
671
],
[
671,
1,
700
]
],
[
[
322,
6,
18701
],
[
18701,
45,
700
]
],
[
[
322,
7,
2903
],
[
2903,
46,
700
]
],
[
[
322,
18,
7669
],
[
7669,
46,
700
]
],
[
[
322,
18,
4360
],
[
4360,
57,
700
]
],
[
[
322,
24,
896
],
[
896,
24,
700
]
],
[
[
322,
25,
982
],
[
982,
63,
700
]
],
[
[
322,
25,
770
],
[
770,
24,
700
]
],
[
[
322,
24,
971
],
[
971,
63,
700
]
]
] | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} (Compound) resembles {v} (Compound)",
"Atorvastatin"
]
],
[
[
"Epirubicin",
"{u} (Compound) binds {v} (Gene)",
"UGT2B7"
],
[
"UGT2B7",
"{u} (Gene) is bound by {v} (Compound)",
"Atorvastatin"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"MMP1"
],
[
"MMP1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Atorvastatin"
]
],
[
[
"Epirubicin",
"{u} (Compound) downregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Atorvastatin"
]
],
[
[
"Epirubicin",
"{u} (Compound) downregulates {v} (Gene)",
"TIMM9"
],
[
"TIMM9",
"{u} (Gene) is downregulated by {v} (Compound)",
"Atorvastatin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
]
] | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Atorvastatin (Compound)
Epirubicin (Compound) binds UGT2B7 (Gene) and UGT2B7 (Gene) is bound by Atorvastatin (Compound)
Epirubicin (Compound) upregulates MMP1 (Gene) and MMP1 (Gene) is upregulated by Atorvastatin (Compound)
Epirubicin (Compound) downregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Atorvastatin (Compound)
Epirubicin (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Atorvastatin (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Epirubicin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Epirubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin |
DB01097 | DB01259 | 1,377 | 392 | [
"DDInter1033",
"DDInter1024"
] | Leflunomide | Lapatinib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. | Major | 2 | [
[
[
1377,
25,
392
]
],
[
[
1377,
21,
28674
],
[
28674,
60,
392
]
],
[
[
1377,
63,
112
],
[
112,
23,
392
]
],
[
[
1377,
25,
637
],
[
637,
63,
392
]
],
[
[
1377,
25,
918
],
[
918,
24,
392
]
],
[
[
1377,
64,
167
],
[
167,
24,
392
]
],
[
[
1377,
63,
10
],
[
10,
24,
392
]
],
[
[
1377,
24,
242
],
[
242,
63,
392
]
],
[
[
1377,
25,
1456
],
[
1456,
64,
392
]
],
[
[
1377,
24,
171
],
[
171,
64,
392
]
]
] | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Leflunomide",
"{u} (Compound) causes {v} (Side Effect)",
"Nail disorder"
],
[
"Nail disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lapatinib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lapatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
],
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
],
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
]
] | Leflunomide (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Lapatinib (Compound)
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Leflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Leflunomide may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Leflunomide may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Leflunomide may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Lapatinib
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib and Lonafarnib may lead to a major life threatening interaction when taken with Lapatinib |
DB11989 | DB13007 | 1,434 | 1,060 | [
"DDInter183",
"DDInter642"
] | Benznidazole | Enfortumab vedotin | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022. | Moderate | 1 | [
[
[
1434,
24,
1060
]
],
[
[
1434,
63,
1593
],
[
1593,
24,
1060
]
],
[
[
1434,
24,
148
],
[
148,
24,
1060
]
],
[
[
1434,
63,
1377
],
[
1377,
25,
1060
]
],
[
[
1434,
63,
1593
],
[
1593,
25,
129
],
[
129,
23,
1060
]
],
[
[
1434,
63,
1439
],
[
1439,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
1434,
63,
14
],
[
14,
24,
913
],
[
913,
23,
1060
]
],
[
[
1434,
63,
350
],
[
350,
63,
1593
],
[
1593,
24,
1060
]
],
[
[
1434,
63,
1480
],
[
1480,
64,
1604
],
[
1604,
23,
1060
]
],
[
[
1434,
63,
112
],
[
112,
23,
129
],
[
129,
23,
1060
]
]
] | [
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
],
[
"Secnidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
]
] | Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Enfortumab vedotin
Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin |
DB00877 | DB12130 | 629 | 1,017 | [
"DDInter1678",
"DDInter1094"
] | Sirolimus | Lorlatinib | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
629,
24,
1017
]
],
[
[
629,
63,
608
],
[
608,
23,
1017
]
],
[
[
629,
63,
590
],
[
590,
24,
1017
]
],
[
[
629,
25,
976
],
[
976,
24,
1017
]
],
[
[
629,
24,
409
],
[
409,
24,
1017
]
],
[
[
629,
64,
311
],
[
311,
24,
1017
]
],
[
[
629,
24,
971
],
[
971,
63,
1017
]
],
[
[
629,
25,
676
],
[
676,
63,
1017
]
],
[
[
629,
24,
1456
],
[
1456,
25,
1017
]
],
[
[
629,
25,
859
],
[
859,
25,
1017
]
]
] | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valdecoxib"
],
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
]
] | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Sirolimus may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Sirolimus may lead to a major life threatening interaction when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Sirolimus may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Lorlatinib
Sirolimus may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole may lead to a major life threatening interaction when taken with Lorlatinib |
DB00543 | DB00981 | 87 | 1,528 | [
"DDInter82",
"DDInter1462"
] | Amoxapine | Physostigmine | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
87,
24,
1528
]
],
[
[
87,
21,
28751
],
[
28751,
60,
1528
]
],
[
[
87,
24,
1511
],
[
1511,
63,
1528
]
],
[
[
87,
24,
543
],
[
543,
24,
1528
]
],
[
[
87,
63,
1503
],
[
1503,
24,
1528
]
],
[
[
87,
1,
623
],
[
623,
63,
1528
]
],
[
[
87,
1,
695
],
[
695,
24,
1528
]
],
[
[
87,
40,
1408
],
[
1408,
24,
1528
]
],
[
[
87,
25,
1011
],
[
1011,
63,
1528
]
],
[
[
87,
25,
497
],
[
497,
64,
1528
]
]
] | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Amoxapine",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Physostigmine"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
],
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Amoxapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Amoxapine",
"{u} (Compound) resembles {v} (Compound)",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Amoxapine",
"{u} (Compound) resembles {v} (Compound)",
"Loxapine"
],
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Physostigmine"
]
]
] | Amoxapine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Physostigmine (Compound)
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Amoxapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Amoxapine (Compound) resembles Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Amoxapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Amoxapine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Amoxapine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Physostigmine |
DB00400 | DB09034 | 353 | 1,313 | [
"DDInter843",
"DDInter1733"
] | Griseofulvin | Suvorexant | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
353,
24,
1313
]
],
[
[
353,
24,
1135
],
[
1135,
62,
1313
]
],
[
[
353,
24,
1213
],
[
1213,
24,
1313
]
],
[
[
353,
24,
1362
],
[
1362,
63,
1313
]
],
[
[
353,
63,
254
],
[
254,
24,
1313
]
],
[
[
353,
62,
1101
],
[
1101,
24,
1313
]
],
[
[
353,
24,
1419
],
[
1419,
25,
1313
]
],
[
[
353,
24,
384
],
[
384,
64,
1313
]
],
[
[
353,
24,
1135
],
[
1135,
62,
1213
],
[
1213,
24,
1313
]
],
[
[
353,
24,
1213
],
[
1213,
23,
1135
],
[
1135,
62,
1313
]
]
] | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Suvorexant"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Suvorexant"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Suvorexant"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Suvorexant"
]
]
] | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Suvorexant
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Suvorexant
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Suvorexant
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Suvorexant |
DB00275 | DB01276 | 217 | 123 | [
"DDInter1330",
"DDInter706"
] | Olmesartan | Exenatide | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available. | Moderate | 1 | [
[
[
217,
24,
123
]
],
[
[
217,
24,
708
],
[
708,
63,
123
]
],
[
[
217,
24,
1573
],
[
1573,
24,
123
]
],
[
[
217,
63,
1685
],
[
1685,
24,
123
]
],
[
[
217,
1,
240
],
[
240,
24,
123
]
],
[
[
217,
1,
911
],
[
911,
63,
123
]
],
[
[
217,
24,
708
],
[
708,
63,
380
],
[
380,
24,
123
]
],
[
[
217,
24,
1573
],
[
1573,
63,
1252
],
[
1252,
23,
123
]
],
[
[
217,
63,
1685
],
[
1685,
23,
1103
],
[
1103,
23,
123
]
],
[
[
217,
24,
1254
],
[
1254,
62,
1103
],
[
1103,
23,
123
]
]
] | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Olmesartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
],
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Olmesartan",
"{u} (Compound) resembles {v} (Compound)",
"Azilsartan medoxomil"
],
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
]
] | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Olmesartan (Compound) resembles Losartan (Compound) and Losartan may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Olmesartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Exenatide
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Exenatide |
DB01229 | DB12825 | 973 | 1,375 | [
"DDInter1378",
"DDInter1032"
] | Paclitaxel (protein-bound) | Lefamulin | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity. | Moderate | 1 | [
[
[
973,
24,
1375
]
],
[
[
973,
63,
112
],
[
112,
23,
1375
]
],
[
[
973,
24,
159
],
[
159,
63,
1375
]
],
[
[
973,
24,
309
],
[
309,
24,
1375
]
],
[
[
973,
25,
976
],
[
976,
24,
1375
]
],
[
[
973,
63,
1101
],
[
1101,
24,
1375
]
],
[
[
973,
25,
676
],
[
676,
63,
1375
]
],
[
[
973,
64,
770
],
[
770,
24,
1375
]
],
[
[
973,
63,
609
],
[
609,
25,
1375
]
],
[
[
973,
24,
913
],
[
913,
25,
1375
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lefamulin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
]
] | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Paclitaxel may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Paclitaxel may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Paclitaxel may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Lefamulin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Lefamulin |
DB00059 | DB00238 | 1,560 | 188 | [
"DDInter1404",
"DDInter1285"
] | Pegaspargase | Nevirapine | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Moderate | 1 | [
[
[
1560,
24,
188
]
],
[
[
1560,
24,
256
],
[
256,
62,
188
]
],
[
[
1560,
24,
168
],
[
168,
23,
188
]
],
[
[
1560,
25,
1101
],
[
1101,
62,
188
]
],
[
[
1560,
24,
1374
],
[
1374,
63,
188
]
],
[
[
1560,
25,
676
],
[
676,
63,
188
]
],
[
[
1560,
24,
1324
],
[
1324,
24,
188
]
],
[
[
1560,
24,
484
],
[
484,
64,
188
]
],
[
[
1560,
25,
1510
],
[
1510,
64,
188
]
],
[
[
1560,
24,
256
],
[
256,
6,
8374
],
[
8374,
45,
188
]
]
] | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nevirapine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nevirapine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nevirapine"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nevirapine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nevirapine"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nevirapine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nevirapine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nevirapine"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nevirapine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Nevirapine"
]
]
] | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Nevirapine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Nevirapine
Pegaspargase may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Nevirapine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine
Pegaspargase may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Nevirapine
Pegaspargase may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Nevirapine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nevirapine (Compound) |
DB00495 | DB12130 | 139 | 1,017 | [
"DDInter1961",
"DDInter1094"
] | Zidovudine | Lorlatinib | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem] | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
139,
24,
1017
]
],
[
[
139,
64,
1101
],
[
1101,
23,
1017
]
],
[
[
139,
24,
175
],
[
175,
24,
1017
]
],
[
[
139,
25,
976
],
[
976,
24,
1017
]
],
[
[
139,
63,
134
],
[
134,
24,
1017
]
],
[
[
139,
25,
676
],
[
676,
63,
1017
]
],
[
[
139,
64,
1064
],
[
1064,
24,
1017
]
],
[
[
139,
23,
752
],
[
752,
24,
1017
]
],
[
[
139,
24,
1619
],
[
1619,
63,
1017
]
],
[
[
139,
24,
1456
],
[
1456,
25,
1017
]
]
] | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Zidovudine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Zidovudine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Zidovudine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Zidovudine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Zidovudine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
]
] | Zidovudine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Zidovudine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Zidovudine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Zidovudine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Zidovudine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Lorlatinib |
DB01142 | DB09078 | 1,264 | 1,228 | [
"DDInter593",
"DDInter1036"
] | Doxepin | Lenvatinib | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. | Moderate | 1 | [
[
[
1264,
24,
1228
]
],
[
[
1264,
62,
112
],
[
112,
23,
1228
]
],
[
[
1264,
64,
1100
],
[
1100,
24,
1228
]
],
[
[
1264,
24,
938
],
[
938,
63,
1228
]
],
[
[
1264,
24,
609
],
[
609,
24,
1228
]
],
[
[
1264,
63,
770
],
[
770,
24,
1228
]
],
[
[
1264,
35,
820
],
[
820,
24,
1228
]
],
[
[
1264,
62,
847
],
[
847,
24,
1228
]
],
[
[
1264,
74,
1164
],
[
1164,
24,
1228
]
],
[
[
1264,
25,
1069
],
[
1069,
25,
1228
]
]
] | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Doxepin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Doxepin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
]
] | Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Doxepin may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Doxepin (Compound) resembles Alimemazine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Doxepin may cause a minor interaction that can limit clinical effects when taken with Atomoxetine and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Doxepin (Compound) resembles Trimipramine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Doxepin may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lenvatinib |
DB00031 | DB10672 | 20 | 297 | [
"DDInter1764",
"DDInter417"
] | Tenecteplase | Clove | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain. | Clove allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
20,
23,
297
]
],
[
[
20,
25,
235
],
[
235,
62,
297
]
],
[
[
20,
24,
578
],
[
578,
23,
297
]
],
[
[
20,
25,
1564
],
[
1564,
23,
297
]
],
[
[
20,
64,
1578
],
[
1578,
23,
297
]
],
[
[
20,
25,
235
],
[
235,
63,
578
],
[
578,
23,
297
]
],
[
[
20,
24,
578
],
[
578,
24,
235
],
[
235,
62,
297
]
],
[
[
20,
25,
1564
],
[
1564,
25,
235
],
[
235,
62,
297
]
],
[
[
20,
25,
1421
],
[
1421,
64,
235
],
[
235,
62,
297
]
],
[
[
20,
24,
1512
],
[
1512,
25,
235
],
[
235,
62,
297
]
]
] | [
[
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
]
] | Tenecteplase may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Clove
Tenecteplase may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a minor interaction that can limit clinical effects when taken with Clove
Tenecteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Tenecteplase may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Clove
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Tenecteplase may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Tenecteplase may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove |
DB00657 | DB01246 | 1,360 | 820 | [
"DDInter1130",
"DDInter45"
] | Mecamylamine | Alimemazine | A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1360,
24,
820
]
],
[
[
1360,
24,
104
],
[
104,
40,
820
]
],
[
[
1360,
24,
401
],
[
401,
24,
820
]
],
[
[
1360,
18,
5833
],
[
5833,
46,
820
]
],
[
[
1360,
21,
28662
],
[
28662,
60,
820
]
],
[
[
1360,
24,
433
],
[
433,
63,
820
]
],
[
[
1360,
63,
1466
],
[
1466,
24,
820
]
],
[
[
1360,
24,
104
],
[
104,
40,
11237
],
[
11237,
40,
820
]
],
[
[
1360,
24,
401
],
[
401,
35,
358
],
[
358,
24,
820
]
],
[
[
1360,
18,
5833
],
[
5833,
46,
11275
],
[
11275,
40,
820
]
]
] | [
[
[
"Mecamylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Mecamylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
]
],
[
[
"Mecamylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Mecamylamine",
"{u} (Compound) downregulates {v} (Gene)",
"ACAT2"
],
[
"ACAT2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Alimemazine"
]
],
[
[
"Mecamylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alimemazine"
]
],
[
[
"Mecamylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Mecamylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Mecamylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Acetophenazine"
],
[
"Acetophenazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
]
],
[
[
"Mecamylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Mecamylamine",
"{u} (Compound) downregulates {v} (Gene)",
"ACAT2"
],
[
"ACAT2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Chlorprothixene"
],
[
"Chlorprothixene",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
]
]
] | Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Mecamylamine (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Alimemazine (Compound)
Mecamylamine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Alimemazine (Compound)
Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Acetophenazine (Compound) and Acetophenazine (Compound) resembles Alimemazine (Compound)
Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) resembles Orphenadrine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Mecamylamine (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles Alimemazine (Compound) |
DB00465 | DB00795 | 886 | 50 | [
"DDInter1010",
"DDInter1725"
] | Ketorolac | Sulfasalazine | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent. | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease. Meta-analysis of 19 randomized controlled trials indicated that sulfasalazine is superior to placebo in inducing remission; however, with no supported evidence of mucosal healing, sulfasalazine is not FDA-recommmended for treatment of Crohn's disease.[A255597,A255602,A255607] | Moderate | 1 | [
[
[
886,
24,
50
]
],
[
[
886,
24,
712
],
[
712,
1,
50
]
],
[
[
886,
6,
10522
],
[
10522,
45,
50
]
],
[
[
886,
7,
7273
],
[
7273,
46,
50
]
],
[
[
886,
63,
305
],
[
305,
24,
50
]
],
[
[
886,
24,
1144
],
[
1144,
24,
50
]
],
[
[
886,
24,
959
],
[
959,
63,
50
]
],
[
[
886,
1,
24
],
[
24,
24,
50
]
],
[
[
886,
25,
1274
],
[
1274,
24,
50
]
],
[
[
886,
25,
848
],
[
848,
63,
50
]
]
] | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
]
],
[
[
"Ketorolac",
"{u} (Compound) binds {v} (Gene)",
"PTGS1"
],
[
"PTGS1",
"{u} (Gene) is bound by {v} (Compound)",
"Sulfasalazine"
]
],
[
[
"Ketorolac",
"{u} (Compound) upregulates {v} (Gene)",
"GPATCH8"
],
[
"GPATCH8",
"{u} (Gene) is upregulated by {v} (Compound)",
"Sulfasalazine"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Ketorolac",
"{u} (Compound) resembles {v} (Compound)",
"Tolmetin"
],
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
]
] | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Ketorolac (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Sulfasalazine (Compound)
Ketorolac (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Sulfasalazine (Compound)
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Ketorolac (Compound) resembles Tolmetin (Compound) and Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Ketorolac may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Ketorolac may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine |
DB01229 | DB06273 | 973 | 980 | [
"DDInter1377",
"DDInter1824"
] | Paclitaxel | Tocilizumab | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023. | Moderate | 1 | [
[
[
973,
24,
980
]
],
[
[
973,
63,
1461
],
[
1461,
23,
980
]
],
[
[
973,
63,
139
],
[
139,
24,
980
]
],
[
[
973,
24,
309
],
[
309,
24,
980
]
],
[
[
973,
24,
110
],
[
110,
63,
980
]
],
[
[
973,
64,
770
],
[
770,
24,
980
]
],
[
[
973,
25,
1011
],
[
1011,
64,
980
]
],
[
[
973,
24,
990
],
[
990,
64,
980
]
],
[
[
973,
24,
1531
],
[
1531,
25,
980
]
],
[
[
973,
63,
1184
],
[
1184,
25,
980
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tocilizumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
],
[
"Polatuzumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
]
]
] | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tocilizumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Paclitaxel may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Paclitaxel may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tocilizumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Tocilizumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may lead to a major life threatening interaction when taken with Tocilizumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Tocilizumab |
DB00712 | DB08886 | 1,274 | 637 | [
"DDInter763",
"DDInter126"
] | Flurbiprofen | Asparaginase Erwinia chrysanthemi | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen. | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to Asparaginase _Erwinia chrysanthemi_. Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase: it has been used as part of multi-agent chemotherapy. In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. | Moderate | 1 | [
[
[
1274,
24,
637
]
],
[
[
1274,
24,
167
],
[
167,
24,
637
]
],
[
[
1274,
25,
1421
],
[
1421,
63,
637
]
],
[
[
1274,
63,
267
],
[
267,
24,
637
]
],
[
[
1274,
64,
663
],
[
663,
24,
637
]
],
[
[
1274,
37,
292
],
[
292,
63,
637
]
],
[
[
1274,
24,
1613
],
[
1613,
63,
637
]
],
[
[
1274,
25,
707
],
[
707,
24,
637
]
],
[
[
1274,
35,
848
],
[
848,
24,
637
]
],
[
[
1274,
75,
126
],
[
126,
24,
637
]
]
] | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
],
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
]
] | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Flurbiprofen may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Flurbiprofen may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Flurbiprofen may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Flurbiprofen may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Flurbiprofen (Compound) resembles Ibuprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Flurbiprofen (Compound) resembles Warfarin (Compound) and Flurbiprofen may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi |
DB00332 | DB01173 | 1,089 | 358 | [
"DDInter970",
"DDInter1349"
] | Ipratropium | Orphenadrine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol] was approved in 1996.[L5894, L5891] | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
1089,
24,
358
]
],
[
[
1089,
24,
211
],
[
211,
1,
358
]
],
[
[
1089,
24,
272
],
[
272,
24,
358
]
],
[
[
1089,
24,
820
],
[
820,
63,
358
]
],
[
[
1089,
24,
1405
],
[
1405,
40,
358
]
],
[
[
1089,
63,
21
],
[
21,
1,
358
]
],
[
[
1089,
6,
4304
],
[
4304,
45,
358
]
],
[
[
1089,
18,
7359
],
[
7359,
57,
358
]
],
[
[
1089,
21,
29232
],
[
29232,
60,
358
]
],
[
[
1089,
35,
19
],
[
19,
24,
358
]
]
] | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Ipratropium",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Ipratropium",
"{u} (Compound) downregulates {v} (Gene)",
"TXNDC9"
],
[
"TXNDC9",
"{u} (Gene) is downregulated by {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Ipratropium",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Ipratropium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
]
] | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Orphenadrine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline (Compound) resembles Orphenadrine (Compound)
Ipratropium (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Orphenadrine (Compound)
Ipratropium (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Orphenadrine (Compound)
Ipratropium (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Orphenadrine (Compound)
Ipratropium (Compound) resembles Hyoscyamine (Compound) and Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine |
DB00445 | DB00831 | 322 | 1,178 | [
"DDInter655",
"DDInter1866"
] | Epirubicin | Trifluoperazine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
322,
24,
1178
]
],
[
[
322,
64,
695
],
[
695,
40,
1178
]
],
[
[
322,
24,
851
],
[
851,
40,
1178
]
],
[
[
322,
24,
9
],
[
9,
1,
1178
]
],
[
[
322,
63,
508
],
[
508,
40,
1178
]
],
[
[
322,
25,
684
],
[
684,
40,
1178
]
],
[
[
322,
7,
3588
],
[
3588,
45,
1178
]
],
[
[
322,
7,
1881
],
[
1881,
46,
1178
]
],
[
[
322,
18,
5235
],
[
5235,
46,
1178
]
],
[
[
322,
6,
3641
],
[
3641,
46,
1178
]
]
] | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"TNNC1"
],
[
"TNNC1",
"{u} (Gene) is bound by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"SREBF2"
],
[
"SREBF2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Epirubicin",
"{u} (Compound) downregulates {v} (Gene)",
"AARS"
],
[
"AARS",
"{u} (Gene) is upregulated by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Epirubicin",
"{u} (Compound) binds {v} (Gene)",
"DHCR7"
],
[
"DHCR7",
"{u} (Gene) is upregulated by {v} (Compound)",
"Trifluoperazine"
]
]
] | Epirubicin may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Trifluoperazine (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine (Compound) resembles Trifluoperazine (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Trifluoperazine (Compound)
Epirubicin may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Trifluoperazine (Compound)
Epirubicin (Compound) upregulates TNNC1 (Gene) and TNNC1 (Gene) is bound by Trifluoperazine (Compound)
Epirubicin (Compound) upregulates SREBF2 (Gene) and SREBF2 (Gene) is upregulated by Trifluoperazine (Compound)
Epirubicin (Compound) downregulates AARS (Gene) and AARS (Gene) is upregulated by Trifluoperazine (Compound)
Epirubicin (Compound) binds DHCR7 (Gene) and DHCR7 (Gene) is upregulated by Trifluoperazine (Compound) |
DB00346 | DB01211 | 472 | 609 | [
"DDInter44",
"DDInter393"
] | Alfuzosin | Clarithromycin | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Major | 2 | [
[
[
472,
25,
609
]
],
[
[
472,
6,
8374
],
[
8374,
45,
609
]
],
[
[
472,
21,
28759
],
[
28759,
60,
609
]
],
[
[
472,
63,
600
],
[
600,
23,
609
]
],
[
[
472,
23,
752
],
[
752,
23,
609
]
],
[
[
472,
24,
770
],
[
770,
24,
609
]
],
[
[
472,
24,
1383
],
[
1383,
63,
609
]
],
[
[
472,
25,
760
],
[
760,
63,
609
]
],
[
[
472,
63,
521
],
[
521,
24,
609
]
],
[
[
472,
1,
1433
],
[
1433,
24,
609
]
]
] | [
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
]
],
[
[
"Alfuzosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Alfuzosin",
"{u} (Compound) causes {v} (Side Effect)",
"Connective tissue disorder"
],
[
"Connective tissue disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Alfuzosin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Alfuzosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
],
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
]
] | Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound)
Alfuzosin (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Clarithromycin (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Alfuzosin may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Alfuzosin (Compound) resembles Doxazosin (Compound) and Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin |
DB00188 | DB00445 | 168 | 322 | [
"DDInter222",
"DDInter655"
] | Bortezomib | Epirubicin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
168,
24,
322
]
],
[
[
168,
5,
11555
],
[
11555,
44,
322
]
],
[
[
168,
7,
7849
],
[
7849,
46,
322
]
],
[
[
168,
18,
19625
],
[
19625,
46,
322
]
],
[
[
168,
7,
7933
],
[
7933,
57,
322
]
],
[
[
168,
18,
1917
],
[
1917,
57,
322
]
],
[
[
168,
21,
28949
],
[
28949,
60,
322
]
],
[
[
168,
24,
112
],
[
112,
62,
322
]
],
[
[
168,
23,
1307
],
[
1307,
62,
322
]
],
[
[
168,
24,
671
],
[
671,
63,
322
]
]
] | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Bortezomib",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Bortezomib",
"{u} (Compound) upregulates {v} (Gene)",
"FRS2"
],
[
"FRS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Bortezomib",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC92"
],
[
"CCDC92",
"{u} (Gene) is upregulated by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Bortezomib",
"{u} (Compound) upregulates {v} (Gene)",
"DDX42"
],
[
"DDX42",
"{u} (Gene) is downregulated by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Bortezomib",
"{u} (Compound) downregulates {v} (Gene)",
"CDC25B"
],
[
"CDC25B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Bortezomib",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoptysis"
],
[
"Haemoptysis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epirubicin"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epirubicin"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
]
] | Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Epirubicin (Compound)
Bortezomib (Compound) upregulates FRS2 (Gene) and FRS2 (Gene) is upregulated by Epirubicin (Compound)
Bortezomib (Compound) downregulates CCDC92 (Gene) and CCDC92 (Gene) is upregulated by Epirubicin (Compound)
Bortezomib (Compound) upregulates DDX42 (Gene) and DDX42 (Gene) is downregulated by Epirubicin (Compound)
Bortezomib (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Epirubicin (Compound)
Bortezomib (Compound) causes Haemoptysis (Side Effect) and Haemoptysis (Side Effect) is caused by Epirubicin (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Epirubicin
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan may cause a minor interaction that can limit clinical effects when taken with Epirubicin
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin |
DB01324 | DB09133 | 178 | 1,527 | [
"DDInter1490",
"DDInter965"
] | Polythiazide | Iothalamic acid | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Moderate | 1 | [
[
[
178,
24,
1527
]
],
[
[
178,
1,
1577
],
[
1577,
24,
1527
]
],
[
[
178,
63,
1648
],
[
1648,
24,
1527
]
],
[
[
178,
63,
1512
],
[
1512,
25,
1527
]
],
[
[
178,
1,
1577
],
[
1577,
40,
504
],
[
504,
24,
1527
]
],
[
[
178,
1,
504
],
[
504,
1,
1577
],
[
1577,
24,
1527
]
],
[
[
178,
63,
1648
],
[
1648,
24,
863
],
[
863,
24,
1527
]
],
[
[
178,
63,
848
],
[
848,
63,
863
],
[
863,
24,
1527
]
],
[
[
178,
54,
19147
],
[
19147,
15,
863
],
[
863,
24,
1527
]
],
[
[
178,
21,
29196
],
[
29196,
60,
863
],
[
863,
24,
1527
]
]
] | [
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
],
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
],
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Polythiazide",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Increased Diuresis"
],
[
"Increased Diuresis",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Amiloride"
],
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Polythiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amiloride"
],
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
]
] | Polythiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Iothalamic acid
Polythiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Polythiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Amiloride and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Amiloride and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Polythiazide (Compound) is included by Increased Diuresis (Pharmacologic Class) and Increased Diuresis (Pharmacologic Class) includes Amiloride (Compound) and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Polythiazide (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Amiloride (Compound) and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid |
DB00526 | DB00552 | 1,555 | 1,238 | [
"DDInter1355",
"DDInter1425"
] | Oxaliplatin | Pentostatin | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Moderate | 1 | [
[
[
1555,
24,
1238
]
],
[
[
1555,
24,
1585
],
[
1585,
1,
1238
]
],
[
[
1555,
24,
1477
],
[
1477,
40,
1238
]
],
[
[
1555,
24,
1539
],
[
1539,
62,
1238
]
],
[
[
1555,
64,
1176
],
[
1176,
23,
1238
]
],
[
[
1555,
25,
246
],
[
246,
62,
1238
]
],
[
[
1555,
63,
1648
],
[
1648,
24,
1238
]
],
[
[
1555,
24,
995
],
[
995,
63,
1238
]
],
[
[
1555,
25,
869
],
[
869,
63,
1238
]
],
[
[
1555,
24,
450
],
[
450,
24,
1238
]
]
] | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
],
[
"Adenosine",
"{u} (Compound) resembles {v} (Compound)",
"Pentostatin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
"Telbivudine",
"{u} (Compound) resembles {v} (Compound)",
"Pentostatin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pentostatin"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pentostatin"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pentostatin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
],
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
]
] | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Adenosine and Adenosine (Compound) resembles Pentostatin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine (Compound) resembles Pentostatin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Pentostatin
Oxaliplatin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Pentostatin
Oxaliplatin may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Pentostatin
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin
Oxaliplatin may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin |
DB11730 | DB11817 | 351 | 1,259 | [
"DDInter1588",
"DDInter165"
] | Ribociclib | Baricitinib | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022. | Major | 2 | [
[
[
351,
25,
1259
]
],
[
[
351,
63,
949
],
[
949,
24,
1259
]
],
[
[
351,
64,
828
],
[
828,
24,
1259
]
],
[
[
351,
24,
1129
],
[
1129,
63,
1259
]
],
[
[
351,
25,
180
],
[
180,
63,
1259
]
],
[
[
351,
64,
384
],
[
384,
25,
1259
]
],
[
[
351,
25,
975
],
[
975,
64,
1259
]
],
[
[
351,
63,
36
],
[
36,
25,
1259
]
],
[
[
351,
24,
564
],
[
564,
64,
1259
]
],
[
[
351,
24,
738
],
[
738,
25,
1259
]
]
] | [
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
],
[
"Human adenovirus e serotype 4 strain cl-68578 antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
],
[
"Lurbinectedin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
],
[
"Abemaciclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
]
] | Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Ribociclib may lead to a major life threatening interaction when taken with Oxycodone and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Ribociclib may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Ribociclib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Ribociclib may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may lead to a major life threatening interaction when taken with Baricitinib
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Baricitinib
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib and Abemaciclib may lead to a major life threatening interaction when taken with Baricitinib
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may lead to a major life threatening interaction when taken with Baricitinib |
DB00436 | DB01276 | 323 | 123 | [
"DDInter179",
"DDInter706"
] | Bendroflumethiazide | Exenatide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available. | Moderate | 1 | [
[
[
323,
24,
123
]
],
[
[
323,
24,
708
],
[
708,
63,
123
]
],
[
[
323,
24,
1573
],
[
1573,
24,
123
]
],
[
[
323,
40,
1577
],
[
1577,
24,
123
]
],
[
[
323,
23,
126
],
[
126,
24,
123
]
],
[
[
323,
63,
176
],
[
176,
24,
123
]
],
[
[
323,
40,
178
],
[
178,
63,
123
]
],
[
[
323,
24,
708
],
[
708,
63,
380
],
[
380,
24,
123
]
],
[
[
323,
24,
1573
],
[
1573,
63,
1252
],
[
1252,
23,
123
]
],
[
[
323,
40,
1577
],
[
1577,
24,
708
],
[
708,
63,
123
]
]
] | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
]
] | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bendroflumethiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bendroflumethiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Bendroflumethiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide |
DB00563 | DB00992 | 663 | 842 | [
"DDInter1174",
"DDInter1182"
] | Methotrexate | Methyl aminolevulinate (topical) | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. It has a role as an antineoplastic agent, a photosensitizing agent, a prodrug and a dermatologic drug. It is functionally related to a 5-aminolevulinic acid. | Moderate | 1 | [
[
[
663,
24,
842
]
],
[
[
663,
21,
28787
],
[
28787,
60,
842
]
],
[
[
663,
24,
246
],
[
246,
63,
842
]
],
[
[
663,
25,
1274
],
[
1274,
24,
842
]
],
[
[
663,
24,
1622
],
[
1622,
24,
842
]
],
[
[
663,
63,
612
],
[
612,
24,
842
]
],
[
[
663,
25,
848
],
[
848,
63,
842
]
],
[
[
663,
25,
213
],
[
213,
36,
842
]
],
[
[
663,
21,
28787
],
[
28787,
60,
246
],
[
246,
63,
842
]
],
[
[
663,
21,
29635
],
[
29635,
60,
161
],
[
161,
24,
842
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methyl aminolevulinate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verteporfin"
],
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
],
[
"Aminolevulinic acid",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Burning sensation"
],
[
"Burning sensation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
]
] | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Methotrexate (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Methyl aminolevulinate (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Methotrexate may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Verteporfin and Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Methotrexate may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Methotrexate may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid (Compound) resembles Methyl aminolevulinate (Compound) and Aminolevulinic acid may lead to a major life threatening interaction when taken with Methyl aminolevulinate
Methotrexate (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Methotrexate (Compound) causes Burning sensation (Side Effect) and Burning sensation (Side Effect) is caused by Sulfadiazine (Compound) and Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate |
DB01050 | DB06700 | 848 | 643 | [
"DDInter900",
"DDInter511"
] | Ibuprofen | Desvenlafaxine | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. Although the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD. Desvenlafaxine has a very similar pharmacological, efficacy, and safety profile as [venlafaxine]. The major difference is the potential for drug interaction since venlafaxine is mainly metabolized by CYP2D6 while desvenlafaxine is conjugated by UGT; therefore, desvenlafaxine is less likely to cause drug-drug interaction when taken with medications affecting the CYP2D6 pathway. | Moderate | 1 | [
[
[
848,
24,
643
]
],
[
[
848,
63,
1100
],
[
1100,
1,
643
]
],
[
[
848,
21,
28709
],
[
28709,
60,
643
]
],
[
[
848,
62,
752
],
[
752,
23,
643
]
],
[
[
848,
24,
1383
],
[
1383,
63,
643
]
],
[
[
848,
25,
292
],
[
292,
63,
643
]
],
[
[
848,
74,
1274
],
[
1274,
24,
643
]
],
[
[
848,
63,
1018
],
[
1018,
24,
643
]
],
[
[
848,
24,
1047
],
[
1047,
24,
643
]
],
[
[
848,
64,
834
],
[
834,
24,
643
]
]
] | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Ibuprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Ibuprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
],
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ibuprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
]
] | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Ibuprofen (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Desvenlafaxine (Compound)
Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Desvenlafaxine
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Ibuprofen may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Ibuprofen (Compound) resembles Flurbiprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Ibuprofen may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine |
DB00620 | DB00703 | 175 | 997 | [
"DDInter1855",
"DDInter1167"
] | Triamcinolone | Methazolamide | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Moderate | 1 | [
[
[
175,
24,
997
]
],
[
[
175,
24,
471
],
[
471,
1,
997
]
],
[
[
175,
6,
8374
],
[
8374,
45,
997
]
],
[
[
175,
21,
29305
],
[
29305,
60,
997
]
],
[
[
175,
24,
1144
],
[
1144,
63,
997
]
],
[
[
175,
24,
1287
],
[
1287,
24,
997
]
],
[
[
175,
63,
176
],
[
176,
24,
997
]
],
[
[
175,
23,
1674
],
[
1674,
63,
997
]
],
[
[
175,
40,
1486
],
[
1486,
63,
997
]
],
[
[
175,
25,
497
],
[
497,
63,
997
]
]
] | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
],
[
"Acetazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Methazolamide"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Methazolamide"
]
],
[
[
"Triamcinolone",
"{u} (Compound) causes {v} (Side Effect)",
"Dysgeusia"
],
[
"Dysgeusia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methazolamide"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
]
] | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide and Acetazolamide (Compound) resembles Methazolamide (Compound)
Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methazolamide (Compound)
Triamcinolone (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Methazolamide (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide
Triamcinolone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide
Triamcinolone may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide |
DB01173 | DB09076 | 358 | 1,116 | [
"DDInter1349",
"DDInter1899"
] | Orphenadrine | Umeclidinium | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%. Maintenance of the airway is controlled by the parasympathetic nervous system, particularly by the abundance of the muscarinic subtype 3 (M3) in the airway smooth muscle. Parasympathetic ganglia are associated with the larger airways while postganglionic fibers innervate the smaller diameter bronchioles contributing to airway resistance. By blocking the M3 muscarinic receptor, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. However, even though umeclidinium monotherapy is well-tolerated for up to 14 days, it is more likely to be used in combination therapy, as the international Gold Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommended the use of two long-acting bronchodilators with differing mechanisms of action to maximize efficacy and minimize adverse effects.[A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product. Later, it was further approved as a combination product with [vilanterol] and [vilanterol]/[fluticasone furoate] under the brand name ANORO ELLIPTA and TRELEGY ELLIPTA respectively.[L44461,L44456]. ANORO ELLIPTA was approved in December 2013 while TRELEGY ELLIPTA was approved in September 2017.[L46881,L46886] | Moderate | 1 | [
[
[
358,
24,
1116
]
],
[
[
358,
24,
849
],
[
849,
24,
1116
]
],
[
[
358,
74,
401
],
[
401,
24,
1116
]
],
[
[
358,
63,
1442
],
[
1442,
24,
1116
]
],
[
[
358,
1,
1405
],
[
1405,
24,
1116
]
],
[
[
358,
40,
508
],
[
508,
24,
1116
]
],
[
[
358,
24,
103
],
[
103,
63,
1116
]
],
[
[
358,
24,
849
],
[
849,
63,
1300
],
[
1300,
24,
1116
]
],
[
[
358,
24,
1511
],
[
1511,
24,
849
],
[
849,
24,
1116
]
],
[
[
358,
74,
401
],
[
401,
24,
849
],
[
849,
24,
1116
]
]
] | [
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
],
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
]
] | Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Orphenadrine (Compound) resembles Promethazine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Orphenadrine (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Orphenadrine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine and Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Orphenadrine (Compound) resembles Promethazine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium |
DB00910 | DB09420 | 1,041 | 1,074 | [
"DDInter1394",
"DDInter953"
] | Paricalcitol | Iodide I-123 | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4). Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared to I-131. | Moderate | 1 | [
[
[
1041,
24,
1074
]
],
[
[
1041,
24,
697
],
[
697,
24,
516
],
[
516,
24,
1074
]
],
[
[
1041,
24,
116
],
[
116,
63,
516
],
[
516,
24,
1074
]
],
[
[
1041,
24,
697
],
[
697,
64,
126
],
[
126,
24,
1074
]
],
[
[
1041,
63,
1335
],
[
1335,
24,
516
],
[
516,
24,
1074
]
],
[
[
1041,
24,
697
],
[
697,
62,
50
],
[
50,
24,
1074
]
],
[
[
1041,
63,
1335
],
[
1335,
1,
902
],
[
902,
24,
1074
]
],
[
[
1041,
63,
1335
],
[
1335,
40,
126
],
[
126,
24,
1074
]
],
[
[
1041,
24,
116
],
[
116,
24,
1004
],
[
1004,
63,
1074
]
],
[
[
1041,
63,
759
],
[
759,
64,
126
],
[
126,
24,
1074
]
]
] | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
],
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
],
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} (Compound) resembles {v} (Compound)",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
],
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
],
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
]
] | Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 |
DB00388 | DB00983 | 1,636 | 480 | [
"DDInter1453",
"DDInter776"
] | Phenylephrine | Formoterol | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting muscarinic antagonists.[L10992,L10989] | Moderate | 1 | [
[
[
1636,
24,
480
]
],
[
[
1636,
24,
1148
],
[
1148,
63,
480
]
],
[
[
1636,
24,
1523
],
[
1523,
25,
480
]
],
[
[
1636,
21,
28719
],
[
28719,
60,
480
]
],
[
[
1636,
25,
1053
],
[
1053,
63,
480
]
],
[
[
1636,
63,
726
],
[
726,
24,
480
]
],
[
[
1636,
24,
1674
],
[
1674,
24,
480
]
],
[
[
1636,
25,
87
],
[
87,
24,
480
]
],
[
[
1636,
64,
21
],
[
21,
24,
480
]
],
[
[
1636,
35,
768
],
[
768,
63,
480
]
]
] | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Formoterol"
]
],
[
[
"Phenylephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Formoterol"
]
],
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Phenylephrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
],
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
]
] | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Formoterol
Phenylephrine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Formoterol (Compound)
Phenylephrine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Betaxolol and Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Phenylephrine may lead to a major life threatening interaction when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Phenylephrine may lead to a major life threatening interaction when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Phenylephrine (Compound) resembles Tapentadol (Compound) and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol and Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol |
DB06403 | DB09038 | 1,204 | 1,450 | [
"DDInter62",
"DDInter636"
] | Ambrisentan | Empagliflozin | Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916] | Moderate | 1 | [
[
[
1204,
24,
1450
]
],
[
[
1204,
24,
1017
],
[
1017,
63,
1450
]
],
[
[
1204,
25,
1510
],
[
1510,
24,
1450
]
],
[
[
1204,
24,
850
],
[
850,
24,
1450
]
],
[
[
1204,
63,
305
],
[
305,
24,
1450
]
],
[
[
1204,
62,
609
],
[
609,
24,
1450
]
],
[
[
1204,
24,
1017
],
[
1017,
63,
1028
],
[
1028,
24,
1450
]
],
[
[
1204,
25,
1510
],
[
1510,
64,
1551
],
[
1551,
24,
1450
]
],
[
[
1204,
63,
305
],
[
305,
24,
1551
],
[
1551,
24,
1450
]
],
[
[
1204,
62,
609
],
[
609,
63,
485
],
[
485,
24,
1450
]
]
] | [
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Ambrisentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Ambrisentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Ambrisentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methyldopa"
],
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
],
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Ambrisentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
]
] | Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Ambrisentan may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Ambrisentan may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Ambrisentan may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Methyldopa and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Ambrisentan may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin |
DB01144 | DB11921 | 1,326 | 1,019 | [
"DDInter540",
"DDInter492"
] | Diclofenamide | Deflazacort | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340] | Moderate | 1 | [
[
[
1326,
24,
1019
]
],
[
[
1326,
63,
959
],
[
959,
24,
1019
]
],
[
[
1326,
24,
1021
],
[
1021,
24,
1019
]
],
[
[
1326,
1,
359
],
[
359,
24,
1019
]
],
[
[
1326,
24,
1385
],
[
1385,
63,
1019
]
],
[
[
1326,
40,
504
],
[
504,
24,
1019
]
],
[
[
1326,
64,
1479
],
[
1479,
24,
1019
]
],
[
[
1326,
24,
1220
],
[
1220,
25,
1019
]
],
[
[
1326,
63,
959
],
[
959,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
1326,
24,
1021
],
[
1021,
63,
1072
],
[
1072,
23,
1019
]
]
] | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Diclofenamide",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Diclofenamide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Diclofenamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
]
]
] | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Diclofenamide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Diclofenamide may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort |
DB00543 | DB01169 | 87 | 57 | [
"DDInter82",
"DDInter120"
] | Amoxapine | Arsenic trioxide | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. | Major | 2 | [
[
[
87,
25,
57
]
],
[
[
87,
23,
112
],
[
112,
23,
57
]
],
[
[
87,
24,
480
],
[
480,
24,
57
]
],
[
[
87,
24,
144
],
[
144,
63,
57
]
],
[
[
87,
40,
867
],
[
867,
24,
57
]
],
[
[
87,
24,
1616
],
[
1616,
64,
57
]
],
[
[
87,
25,
1154
],
[
1154,
64,
57
]
],
[
[
87,
24,
485
],
[
485,
25,
57
]
],
[
[
87,
25,
1425
],
[
1425,
25,
57
]
],
[
[
87,
64,
1494
],
[
1494,
25,
57
]
]
] | [
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Amoxapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Amoxapine",
"{u} (Compound) resembles {v} (Compound)",
"Olanzapine"
],
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
]
] | Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Amoxapine (Compound) resembles Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may lead to a major life threatening interaction when taken with Arsenic trioxide
Amoxapine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Arsenic trioxide
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Arsenic trioxide
Amoxapine may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Arsenic trioxide
Amoxapine may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Arsenic trioxide |
DB00569 | DB01404 | 553 | 757 | [
"DDInter775",
"DDInter820"
] | Fondaparinux | Ginseng | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
553,
24,
757
]
],
[
[
553,
64,
25
],
[
25,
24,
757
]
],
[
[
553,
25,
578
],
[
578,
63,
757
]
],
[
[
553,
25,
1226
],
[
1226,
24,
757
]
],
[
[
553,
64,
25
],
[
25,
24,
578
],
[
578,
63,
757
]
],
[
[
553,
25,
578
],
[
578,
63,
25
],
[
25,
24,
757
]
],
[
[
553,
25,
1226
],
[
1226,
64,
25
],
[
25,
24,
757
]
],
[
[
553,
25,
1347
],
[
1347,
62,
245
],
[
245,
24,
757
]
],
[
[
553,
64,
1432
],
[
1432,
64,
25
],
[
25,
24,
757
]
],
[
[
553,
64,
1578
],
[
1578,
25,
25
],
[
25,
24,
757
]
]
] | [
[
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tirofiban"
],
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tirofiban"
],
[
"Tirofiban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
]
] | Fondaparinux may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Fondaparinux may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Fondaparinux may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Fondaparinux may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Fondaparinux may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Fondaparinux may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Fondaparinux may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Fondaparinux may lead to a major life threatening interaction when taken with Abciximab and Abciximab may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Fondaparinux may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng |
DB01009 | DB06754 | 935 | 707 | [
"DDInter1009",
"DDInter471"
] | Ketoprofen | Danaparoid | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. Danaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously. | Major | 2 | [
[
[
935,
25,
707
]
],
[
[
935,
63,
121
],
[
121,
24,
707
]
],
[
[
935,
24,
222
],
[
222,
24,
707
]
],
[
[
935,
24,
738
],
[
738,
63,
707
]
],
[
[
935,
25,
235
],
[
235,
64,
707
]
],
[
[
935,
64,
1172
],
[
1172,
25,
707
]
],
[
[
935,
63,
702
],
[
702,
25,
707
]
],
[
[
935,
25,
1213
],
[
1213,
25,
707
]
],
[
[
935,
24,
848
],
[
848,
25,
707
]
],
[
[
935,
40,
886
],
[
886,
25,
707
]
]
] | [
[
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Ketoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Ketorolac"
],
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
]
] | Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Ketoprofen may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Danaparoid
Ketoprofen may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Danaparoid
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Danaparoid
Ketoprofen may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Danaparoid
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Danaparoid
Ketoprofen (Compound) resembles Ketorolac (Compound) and Ketorolac may lead to a major life threatening interaction when taken with Danaparoid |
DB01166 | DB12364 | 477 | 1,421 | [
"DDInter379",
"DDInter200"
] | Cilostazol | Betrixaban | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients . | Major | 2 | [
[
[
477,
25,
1421
]
],
[
[
477,
23,
297
],
[
297,
23,
1421
]
],
[
[
477,
23,
944
],
[
944,
62,
1421
]
],
[
[
477,
64,
1091
],
[
1091,
24,
1421
]
],
[
[
477,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
477,
25,
1339
],
[
1339,
63,
1421
]
],
[
[
477,
63,
336
],
[
336,
24,
1421
]
],
[
[
477,
25,
760
],
[
760,
24,
1421
]
],
[
[
477,
24,
1412
],
[
1412,
63,
1421
]
],
[
[
477,
63,
714
],
[
714,
25,
1421
]
]
] | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betrixaban"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betrixaban"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
],
[
"Calaspargase pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
]
] | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Cilostazol may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Cilostazol may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Cilostazol may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Betrixaban |
DB00445 | DB00743 | 322 | 808 | [
"DDInter655",
"DDInter792"
] | Epirubicin | Gadobenic acid | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. As gadobenate dimeglumine is specifically taken up by hepatocytes and excreted through the biliary system, it is a useful contrast agent for liver MRI. Gadobenate dimeglumine was approved by the FDA in November 2004 under the brand name MultiHance. | Moderate | 1 | [
[
[
322,
24,
808
]
],
[
[
322,
21,
29804
],
[
29804,
60,
808
]
],
[
[
322,
25,
1327
],
[
1327,
63,
808
]
],
[
[
322,
24,
589
],
[
589,
24,
808
]
],
[
[
322,
24,
896
],
[
896,
63,
808
]
],
[
[
322,
63,
134
],
[
134,
24,
808
]
],
[
[
322,
35,
51
],
[
51,
24,
808
]
],
[
[
322,
35,
77
],
[
77,
63,
808
]
],
[
[
322,
25,
17
],
[
17,
24,
808
]
],
[
[
322,
21,
29804
],
[
29804,
60,
726
],
[
726,
24,
808
]
]
] | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Blood lactate dehydrogenase increased"
],
[
"Blood lactate dehydrogenase increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gadobenic acid"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Epirubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Epirubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Blood lactate dehydrogenase increased"
],
[
"Blood lactate dehydrogenase increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Betaxolol"
],
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
]
] | Epirubicin (Compound) causes Blood lactate dehydrogenase increased (Side Effect) and Blood lactate dehydrogenase increased (Side Effect) is caused by Gadobenic acid (Compound)
Epirubicin may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid
Epirubicin (Compound) resembles Daunorubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid
Epirubicin (Compound) resembles Idarubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid
Epirubicin may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid
Epirubicin (Compound) causes Blood lactate dehydrogenase increased (Side Effect) and Blood lactate dehydrogenase increased (Side Effect) is caused by Betaxolol (Compound) and Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid |
DB00175 | DB00877 | 681 | 629 | [
"DDInter1509",
"DDInter1678"
] | Pravastatin | Sirolimus | Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991. Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex. | Moderate | 1 | [
[
[
681,
24,
629
]
],
[
[
681,
6,
4973
],
[
4973,
45,
629
]
],
[
[
681,
21,
28898
],
[
28898,
60,
629
]
],
[
[
681,
24,
1040
],
[
1040,
63,
629
]
],
[
[
681,
24,
1555
],
[
1555,
24,
629
]
],
[
[
681,
1,
1463
],
[
1463,
24,
629
]
],
[
[
681,
35,
467
],
[
467,
24,
629
]
],
[
[
681,
24,
609
],
[
609,
64,
629
]
],
[
[
681,
25,
1377
],
[
1377,
64,
629
]
],
[
[
681,
63,
581
],
[
581,
25,
629
]
]
] | [
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Pravastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Pravastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Pravastatin",
"{u} (Compound) resembles {v} (Compound)",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Pravastatin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Pravastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
]
] | Pravastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Pravastatin (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Sirolimus (Compound)
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Pravastatin (Compound) resembles Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Pravastatin (Compound) resembles Simvastatin (Compound) and Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Sirolimus
Pravastatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Sirolimus
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Sirolimus |
DB01082 | DB01099 | 1,448 | 1,272 | [
"DDInter1713",
"DDInter744"
] | Streptomycin | Flucytosine | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis. | A fluorinated cytosine analog that is used as an antifungal agent. | Moderate | 1 | [
[
[
1448,
24,
1272
]
],
[
[
1448,
21,
28787
],
[
28787,
60,
1272
]
],
[
[
1448,
63,
311
],
[
311,
24,
1272
]
],
[
[
1448,
24,
445
],
[
445,
63,
1272
]
],
[
[
1448,
64,
1441
],
[
1441,
24,
1272
]
],
[
[
1448,
35,
416
],
[
416,
63,
1272
]
],
[
[
1448,
25,
1329
],
[
1329,
63,
1272
]
],
[
[
1448,
21,
28787
],
[
28787,
60,
485
],
[
485,
24,
1272
]
],
[
[
1448,
63,
311
],
[
311,
24,
50
],
[
50,
24,
1272
]
],
[
[
1448,
24,
445
],
[
445,
63,
485
],
[
485,
24,
1272
]
]
] | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Streptomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Flucytosine"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
],
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
],
[
"Givosiran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Streptomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacitracin"
],
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Streptomycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Streptomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gallium nitrate"
],
[
"Gallium nitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Streptomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
],
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
],
[
"Givosiran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
]
] | Streptomycin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Flucytosine (Compound)
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran and Givosiran may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Streptomycin may lead to a major life threatening interaction when taken with Bacitracin and Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Streptomycin (Compound) resembles Kanamycin (Compound) and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Streptomycin may lead to a major life threatening interaction when taken with Gallium nitrate and Gallium nitrate may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Streptomycin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pentamidine (Compound) and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran and Givosiran may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine |
DB00569 | DB01225 | 553 | 500 | [
"DDInter775",
"DDInter645"
] | Fondaparinux | Enoxaparin | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding.[A228178,A228313] | Major | 2 | [
[
[
553,
25,
500
]
],
[
[
553,
6,
4089
],
[
4089,
45,
500
]
],
[
[
553,
21,
29964
],
[
29964,
60,
500
]
],
[
[
553,
23,
1631
],
[
1631,
62,
500
]
],
[
[
553,
24,
1004
],
[
1004,
63,
500
]
],
[
[
553,
24,
311
],
[
311,
24,
500
]
],
[
[
553,
63,
1230
],
[
1230,
24,
500
]
],
[
[
553,
25,
1317
],
[
1317,
25,
500
]
],
[
[
553,
25,
840
],
[
840,
64,
500
]
],
[
[
553,
64,
598
],
[
598,
25,
500
]
]
] | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
]
],
[
[
"Fondaparinux",
"{u} (Compound) binds {v} (Gene)",
"SERPINC1"
],
[
"SERPINC1",
"{u} (Gene) is bound by {v} (Compound)",
"Enoxaparin"
]
],
[
[
"Fondaparinux",
"{u} (Compound) causes {v} (Side Effect)",
"Spinal haematoma"
],
[
"Spinal haematoma",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enoxaparin"
]
],
[
[
"Fondaparinux",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxaparin"
]
],
[
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
],
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
],
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dipyridamole"
],
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nabumetone"
],
[
"Nabumetone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
]
]
] | Fondaparinux (Compound) binds SERPINC1 (Gene) and SERPINC1 (Gene) is bound by Enoxaparin (Compound)
Fondaparinux (Compound) causes Spinal haematoma (Side Effect) and Spinal haematoma (Side Effect) is caused by Enoxaparin (Compound)
Fondaparinux may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Enoxaparin
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Fondaparinux may lead to a major life threatening interaction when taken with Dipyridamole and Dipyridamole may lead to a major life threatening interaction when taken with Enoxaparin
Fondaparinux may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may lead to a major life threatening interaction when taken with Enoxaparin
Fondaparinux may lead to a major life threatening interaction when taken with Nabumetone and Nabumetone may lead to a major life threatening interaction when taken with Enoxaparin |
DB06772 | DB11791 | 310 | 785 | [
"DDInter259",
"DDInter287"
] | Cabazitaxel | Capmatinib | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019. | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence of _MET_ amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%. This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020, for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day. As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib's benefit in confirmatory trials. Capmatinib was approved by Health Canada on June 8, 2022. | Moderate | 1 | [
[
[
310,
24,
785
]
],
[
[
310,
63,
1324
],
[
1324,
24,
785
]
],
[
[
310,
24,
868
],
[
868,
24,
785
]
],
[
[
310,
24,
1320
],
[
1320,
63,
785
]
],
[
[
310,
64,
1064
],
[
1064,
24,
785
]
],
[
[
310,
24,
1017
],
[
1017,
64,
785
]
],
[
[
310,
24,
1604
],
[
1604,
25,
785
]
],
[
[
310,
63,
609
],
[
609,
25,
785
]
],
[
[
310,
25,
1510
],
[
1510,
25,
785
]
],
[
[
310,
64,
1377
],
[
1377,
25,
785
]
]
] | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
],
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
],
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
]
] | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Cabazitaxel may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Capmatinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Capmatinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Capmatinib
Cabazitaxel may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Capmatinib
Cabazitaxel may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Capmatinib |
DB00717 | DB06168 | 1,197 | 1,531 | [
"DDInter1312",
"DDInter281"
] | Norethisterone | Canakinumab | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [norethynodrel] and [lynestrenol]. Norethisterone mimics the actions of endogenous [progesterone], albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy.[L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962. | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients. | Moderate | 1 | [
[
[
1197,
24,
1531
]
],
[
[
1197,
1,
873
],
[
873,
24,
1531
]
],
[
[
1197,
24,
1362
],
[
1362,
63,
1531
]
],
[
[
1197,
25,
1476
],
[
1476,
63,
1531
]
],
[
[
1197,
24,
1213
],
[
1213,
24,
1531
]
],
[
[
1197,
63,
1031
],
[
1031,
24,
1531
]
],
[
[
1197,
40,
167
],
[
167,
24,
1531
]
],
[
[
1197,
25,
1096
],
[
1096,
24,
1531
]
],
[
[
1197,
64,
1101
],
[
1101,
24,
1531
]
],
[
[
1197,
63,
581
],
[
581,
25,
1531
]
]
] | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Norgestimate"
],
[
"Norgestimate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Norethisterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Norethisterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Norethisterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
]
]
] | Norethisterone (Compound) resembles Norgestimate (Compound) and Norgestimate may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Norethisterone may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Norethisterone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Norethisterone may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Norethisterone may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Canakinumab |
DB00549 | DB06077 | 522 | 879 | [
"DDInter1955",
"DDInter1102"
] | Zafirlukast | Lumateperone | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia. It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology of schizophrenia.[A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia. Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. Both characteristics lend to a more favourable adverse effect profile and ultimately safer drug.[A189093,L10908] | Moderate | 1 | [
[
[
522,
24,
879
]
],
[
[
522,
24,
214
],
[
214,
63,
879
]
],
[
[
522,
24,
392
],
[
392,
24,
879
]
],
[
[
522,
63,
597
],
[
597,
24,
879
]
],
[
[
522,
23,
222
],
[
222,
24,
879
]
],
[
[
522,
24,
129
],
[
129,
64,
879
]
],
[
[
522,
24,
1419
],
[
1419,
25,
879
]
],
[
[
522,
24,
214
],
[
214,
63,
1281
],
[
1281,
63,
879
]
],
[
[
522,
24,
392
],
[
392,
24,
214
],
[
214,
63,
879
]
],
[
[
522,
63,
597
],
[
597,
24,
214
],
[
214,
63,
879
]
]
] | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
]
] | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lumateperone
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Lumateperone
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone |
DB09038 | DB12130 | 1,450 | 1,017 | [
"DDInter636",
"DDInter1094"
] | Empagliflozin | Lorlatinib | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
1450,
24,
1017
]
],
[
[
1450,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
1450,
63,
590
],
[
590,
24,
1017
]
],
[
[
1450,
24,
214
],
[
214,
24,
1017
]
],
[
[
1450,
24,
971
],
[
971,
63,
1017
]
],
[
[
1450,
63,
1220
],
[
1220,
25,
1017
]
],
[
[
1450,
24,
785
],
[
785,
25,
1017
]
],
[
[
1450,
24,
241
],
[
241,
64,
1017
]
],
[
[
1450,
24,
1612
],
[
1612,
62,
1101
],
[
1101,
23,
1017
]
],
[
[
1450,
63,
590
],
[
590,
63,
1101
],
[
1101,
23,
1017
]
]
] | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
],
[
"Capmatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
],
[
"Erdafitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
]
] | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib and Capmatinib may lead to a major life threatening interaction when taken with Lorlatinib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may lead to a major life threatening interaction when taken with Lorlatinib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib |
DB09098 | DB12825 | 98 | 1,375 | [
"DDInter1700",
"DDInter1032"
] | Somatrem | Lefamulin | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity. | Moderate | 1 | [
[
[
98,
24,
1375
]
],
[
[
98,
24,
159
],
[
159,
63,
1375
]
],
[
[
98,
63,
1532
],
[
1532,
24,
1375
]
],
[
[
98,
64,
1101
],
[
1101,
24,
1375
]
],
[
[
98,
24,
1320
],
[
1320,
24,
1375
]
],
[
[
98,
62,
608
],
[
608,
24,
1375
]
],
[
[
98,
63,
1069
],
[
1069,
25,
1375
]
],
[
[
98,
24,
877
],
[
877,
64,
1375
]
],
[
[
98,
24,
351
],
[
351,
25,
1375
]
],
[
[
98,
24,
159
],
[
159,
63,
966
],
[
966,
24,
1375
]
]
] | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Somatrem",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Somatrem",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
]
] | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Somatrem may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Somatrem may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lefamulin
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Lefamulin
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Lefamulin
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin |
DB01377 | DB09100 | 1,283 | 320 | [
"DDInter1119",
"DDInter1799"
] | Magnesium oxide | Thyroid, porcine | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet. Currently, patients are more likely to be treated with [levothyroxine]. Thyroid extracts were never FDA approved as their use in the United States predates the FDA. | Moderate | 1 | [
[
[
1283,
24,
320
]
],
[
[
1283,
24,
460
],
[
460,
63,
320
]
],
[
[
1283,
63,
1411
],
[
1411,
24,
320
]
],
[
[
1283,
24,
1596
],
[
1596,
24,
320
]
],
[
[
1283,
64,
1231
],
[
1231,
24,
320
]
],
[
[
1283,
24,
460
],
[
460,
24,
428
],
[
428,
63,
320
]
],
[
[
1283,
24,
428
],
[
428,
63,
837
],
[
837,
24,
320
]
],
[
[
1283,
24,
286
],
[
286,
63,
417
],
[
417,
23,
320
]
],
[
[
1283,
63,
1411
],
[
1411,
63,
417
],
[
417,
23,
320
]
],
[
[
1283,
63,
245
],
[
245,
24,
417
],
[
417,
23,
320
]
]
] | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Magnesium oxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thyroid, porcine"
]
]
] | Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Magnesium oxide may lead to a major life threatening interaction when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine |
DB00357 | DB09570 | 1,051 | 1,480 | [
"DDInter71",
"DDInter1002"
] | Aminoglutethimide | Ixazomib | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454) | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration. | Moderate | 1 | [
[
[
1051,
24,
1480
]
],
[
[
1051,
24,
1598
],
[
1598,
63,
1480
]
],
[
[
1051,
24,
310
],
[
310,
24,
1480
]
],
[
[
1051,
62,
168
],
[
168,
24,
1480
]
],
[
[
1051,
24,
129
],
[
129,
25,
1480
]
],
[
[
1051,
24,
1598
],
[
1598,
63,
1094
],
[
1094,
24,
1480
]
],
[
[
1051,
24,
310
],
[
310,
24,
987
],
[
987,
63,
1480
]
],
[
[
1051,
62,
168
],
[
168,
24,
987
],
[
987,
63,
1480
]
],
[
[
1051,
24,
307
],
[
307,
24,
98
],
[
98,
24,
1480
]
],
[
[
1051,
62,
168
],
[
168,
63,
440
],
[
440,
24,
1480
]
]
] | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
],
[
"Vibrio cholerae CVD 103-HgR strain live antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
],
[
"Vibrio cholerae CVD 103-HgR strain live antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
],
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
]
] | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ixazomib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.